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Riassunto 
 
Nell‟ambito delle scienze biotecnologiche, gli analoghi oligonucleotidici occupano un 
ruolo importante. Essi, infatti, essendo in grado di legare targets nucleotidici naturali 
e non naturali contribuiscono allo sviluppo di strategie terapeutiche o diagnostiche e 
di nuovi materiali. 
Tra gli analoghi oligonucleotidici di maggiore successo vi sono gli acidi peptido 
nucleici (PNA da Peptide Nucleic Acids), ideati da Peter Nielsen nel 1991. 
I PNA (Figura 1) sono analoghi aciclici del DNA in cui lo scheletro zucchero-fosfato 
dei normali acidi nucleici è completamente sostituito da una struttura 
pseudopeptidica, in cui l‟unità ripetitiva consiste in una N-(2-amminoetil)glicina (aeg) 
che porta la base eterociclica legata all‟azoto glicinico mediante un ponte 
metilencarbonilico (Nielsen et. al, 1991) .  
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Figura 1: Confronto tra PNA e DNA. 
 
Gli aegPNA riconoscono DNA e RNA complementari in maniera specifica. Essi 
formano, infatti, complessi molto stabili con DNA e RNA, obbedendo allo schema di 
legame ad idrogeno di Watson-Crick, con un‟affinità maggiore rispetto ad 
oligonucleotidi convenzionali o analoghi (Egholm et al., 1993); riconoscono, inoltre, 
sequenze duplex omopuriniche di DNA a cui si legano formando stabili triplex PNA-
DNA-PNA (Nielsen et al., 1994).  
Gli aegPNA risultano chimicamente stabili e non suscettibili di degradazione 
enzimatica da parte di nucleasi o proteasi, sono, di conseguenza molto biostabili sia 
nel siero umano che in estratti cellulari (Uhlmann  et al., 1998). Inoltre sono achirali e 
privi di carica. L‟achiralità fa sì che possano essere sintetizzati senza nessuna 
procedura stereoselettiva, la natura non carica, invece, determina un aumento di 
stabilità delle duplex PNA-DNA(RNA) rispetto alle homoduplex naturali grazie alla 
perdita delle repulsioni elettrostatiche. 
I PNA sono molto interessanti dal punto di vista biologico per lo sviluppo di strategie 
terapeutiche. Infatti, essi possono fungere da agenti antisenso (Nielsen et al., 1993), 
per la loro capacità di inibire la traduzione riconoscendo mRNA complementari, da 
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agenti antigene (Nielsen et al., 1994), per la modulazione della trascrizione e 
replicazione, oltre che da inibitori di enzimi quali telomerasi, data la loro capacità di 
legarsi alla subunità oligonucleotidica delle ribonucleoproteine. L‟azione antisenso 
dei PNA è dovuta al blocco sterico nel complesso PNA-RNA del meccanismo di 
traduzione. Per quanto riguarda l‟azione antigenica essa dipende dalla formazione di 
triple eliche del tipo PNA-DNA-PNA e più raramente DNA-PNA-DNA che blocca il 
processo di trascrizione. Tali complessi creano un ingombro strutturale tale da 
bloccare la normale funzione dell‟RNA polimerasi. 
 
 
 
 
 
 
Figura 2: Illustrazione schematica di  (a) Normale espressione genica, (b) inibizione 
antisenso, (c) inibizione antigenica. 
 
 
Anche nel campo della diagnostica, i PNA hanno dato un notevole 
contributo.Oligomeri di PNA mostrano un‟elevata specificità di legame con un DNA 
complementare (stringenza): ciò significa che gli accoppiamenti errati tra basi sono 
più destabilizzanti nel caso di duplex PNA/DNA (ma anche PNA/RNA) piuttosto che 
in duplex DNA/DNA. Grazie alla loro alta stringenza nel riconoscimento di target 
naturali, essi sono stati utilizzati con successo per rivelare la presenza di mutazioni 
geniche puntiformi, come nel caso del gene CFTR della fibrosi cistica (Carlsson et 
al., 1996), oggetto tuttora di studio di molti gruppi di ricerca internazionali. 
Sin dall‟introduzione degli aegPNA nel 1991, sono stati pubblicati molti studi su 
modifiche a PNA, effettuate allo scopo di ottenere oligomeri con caratteristiche e 
funzioni ottimizzate, quali la scarsa solubilità in soluzioni acquose, l‟ambiguità di 
orientamento (parallelo/antiparallelo) nel legame al DNA, e lo scarso uptake cellulare 
(Uhlmann et al, 1998). Le modificazioni ai PNA più esplorate hanno riguardato lo 
scheletro amminoetilglicinico ed il linker metilencarbonilico (modifiche di 1a 
generazione). Sicuramente una delle più importanti modifiche consiste 
nell‟allungamento della struttura dell‟aegPNA, mediante l‟aggiunta di un gruppo 
metilenico al backbone poliammidico o al linker, come ad esempio nel caso dei PNA 
con unità ripetitive di N-(2-aminoetil)-β-alanina, o dei PNA in cui le nucleobasi sono 
legate tramite un ponte etilene-carbonilico. È stato riscontrato comunque che nelle 
modifiche di prima generazione l‟unica sostituzione tollerata ha riguardato la 
posizione α della glicina. 
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Tra le modifiche di 2a generazione ai PNA, molti lavori sono stati orientati alla 
progettazione di molecole aventi un backbone ciclico (Gangamani et al., 1999 e 
Kumar et al., 2000). Questi tipi di modifiche, che implicano la connessione di 
differenti porzioni dello scheletro di PNA, introducono restrizioni conformazionali e/o 
stereocentri nel polimero risultante, conferendogli interessanti proprietà di 
ibridazione. In quest‟ambito gli amminoprolil PNA (ampPNA) sono risultati i composti 
che hanno suscitato maggiore interesse. Oligomeri di aegPNA, contenenti una 
singola unità di amminoprolil PNA all‟N-terminale, hanno mostrato una singolare 
capacità di discriminazione tra il legame antiparallelo rispetto a quello parallelo al 
DNA. Oligomeri formati interamente da monomeri di ampPNA invece, non hanno 
mostrato capacità d‟ibridazione verso target nucleotidici naturali. 
Sorprendentemente, il polimero in cui i monomeri di aegPNA si alternano a quelli di 
ampPNA ha mostrato un‟affinità di legame al DNA più alta rispetto all‟oligomero 
formato interamente da aegPNA. 
Un‟altra interessante classe di analoghi di PNA è basata su uno scheletro 
diamminoacidico, in cui la nucleobase è legata attraverso un legame ammidico ad 
uno dei due ammino gruppi. In particolare, è stato recentemente dimostrato che 
l‟analogo politiminico di PNA basato sulla D- o L-ornitina (3, Figura 3) lega RNA 
complementari formando strutture a tripla elica (Sforza et al., 2002). 
Gli analoghi di PNA, finora presentati, vengono definiti nucleopeptidi. Con tale 
termine si indica una classe di molecole, di significativa importanza biomedica, 
contenti una struttura peptidica coniugata alle nucleobasi del DNA (o RNA) 
attraverso differenti linker (Roviello et al., 2010). 
In questo contesto si inserisce la ricerca svolta dalla candidata durante il periodo di 
dottorato che ha previsto la sintesi, la caratterizzazione e gli studi di ibridazione di un 
nuovo analogo nucleopeptidico chirale, denominato dabPNA (2, Figura 3). 
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Figura 3: Confronto tra aegPNA, dabPNA e ornPNA. 
 
 
Il nuovo analogo possiede un‟unità monomerica costituita dall‟ acido 
2,4-diamminobutanoico (DABA) a cui è  connesso la base eterociclica mediante un 
legame ammidico, mentre l‟ammino gruppo in posizione γ è implicato nella 
polimerizzazione per dare lo scheletro poliammidico. Tale monomero, quindi, si può 
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considerare come l‟analogo aciclico degli ampPNA, e si differenzia strutturalmente 
dagli aegPNA  per la presenza di un atomo in meno nel backbone, che pertanto 
risulta più corto, e per una maggiore distanza tra la base azotata ed il backbone, 
dovuta alla presenza di un atomo in più.  
La polimerizzazione di questo monomero porta ad una nucleopoliammide chirale con 
scheletro γ-peptidico (nucleo-γ-peptide), a differenza dello scheletro pseudopeptidico 
achirale degli aegPNA.  
Sono vari i motivi che  hanno spinto a basare il nuovo analogo sul DABA. Inanzitutto, 
l‟ acido 2,4-diamminobutanoico è un amminoacido non-proteico ritrovato in natura nei 
semi e nei tessuti vegetali di Lathyrus Silvestris L.: il DABA è distribuito per circa il 
15% nei cloroplasti e per meno del 75% nei vacuoli intracellulari (Foster et al., 1987). 
Un altro motivo che ci ha portato alla scelta del DABA è che l‟acido poli(2,4-
diaminobutanoico), PDBA, ottenuto mediante  polimerizzazione del DABA, è stato 
recentemente utilizzato al posto della polilisina in un nuovo sistema di trasporto del 
gene dell‟Interleuchina-12, permettendo di ottenere un‟alta efficienza di trasfezione. 
In particolare, sono stati studiati in vivo gli effetti antitumorali dell‟immunoterapia di 
una cellula dendritica, sfruttando il trasporto intratumorale, mediato dal PDBA, del 
gene dell‟Interleuchina-12; da tali studi è stato evidenziato che questi sistemi 
sopprimono significativamente la crescita neoplastica (Iwashita et al., 2005). 
Inoltre, il DABA insieme ad altri diamminoacidi ed alle nucleobasi, è stato rinvenuto 
nel suolo del meteorite caduto nel 1969 a Murchison  (Meierhenrich et al., 2005) ed 
in virtù di questo nucleopeptidi basati su questi diamminoacidi sono stati proposti 
come costituenti del materiale genetico primordiale (Meierhenrich et al., 2004 e 
Nielsen, 2007). Da tale osservazione, si evince che la sintesi di polimeri basati su 
diamminoacidi, come il DABA, potrebbe contribuire allo studio del ruolo dei 
nucleopeptidi come materiale prebiotico in un “mondo a PNA” che, secondo recenti 
ipotesi scientifiche, potrebbe successivamente aver portato all‟attuale mondo basato 
su DNA/RNA/proteine.  
Altra osservazione che ci faceva propendere verso la scelta del DABA e che 
l‟analogo basato su di esso è un nucleo-γ-peptide e da letteratura è nota la 
resistenza dei γ-peptidi alla degradazione enzimatica. 
La prima fase della ricerca ha riguardato la sintesi  dell‟unità monomerica 
nucleoamminoacidica  chirale  tL-dab (4, Schema1) coniugando due bulding block : il 
diamminoacido Boc-L-DAB(Fmoc)-OH (1, Schema 1) e la timina carbossimetilata (3, 
Schema 1), entrambi presenti in commercio. In particolare la sintesi del tL-dab ha 
previsto la rimozione selettiva del gruppo Boc con acido trifluoroacetico a 50 °C dal 
composto ottenendo l‟ammino gruppo in α libero. Il prodotto così ottenuto (2), 
caratterizzato mediante 1H-NMR ed LC-ESIMS, è stato successivamente coniugato 
con l‟acido timinil-1-acetico in differenti condizioni sintetiche. I migliori risultati sono 
stati ottenuti utilizzando HATU come attivante, DIPEA come base e DMF come 
solvente (resa 72%, Schema 1). 
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Schema 1: Sintesi dell‟ unità monometrica tL-dab. 
 
 
Il monomero tL-dab, purificato mediante HPLC semipreparativa e caratterizzato 
mediante 1H/13C NMR ed LC-ESI-MS, è stato, successivamente oligomerizzato per 
ottenere il dodecamero politiminico (tL-dab)12 (5, Schema 2). In particolare, la sintesi 
del nuovo nucleopeptide è avvenuta manualmente in fase solida mediante strategia 
Fmoc utilizzando HATU/TMP come sistema attivante in NMP/DMF (1:4, v/v), 
condizione che assicura la conservazione della chiralità durante ogni step sintetico 
(Corradini et al.,2001).  
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Schema 2: Sintesi dell‟ oligomero (tL-dab)12 
 
6 
 
L‟oligomero (tL-dab)12 ottenuto è stato rimosso dal supporto solido mediante 
trattamento acido, precipitato in etere etilico freddo e recuperato dopo 
centrifugazione. In seguito, è stato purificato mediante RP-HPLC semipreparativa e 
successivamente caratterizzato mediante LC-ESIMS. 
L‟abilità del nuovo polimero sintetizzato nel legare acidi nucleici complementari è 
stata studiata al fine di esplorare il suo possibile utilizzo nelle strategie terapeutiche 
antisenso/antigene o in applicazioni diagnostiche.  
Esperimenti di dicroismo circolare (CD), associati a curve di denaturazione termica 
UV, hanno mostrato che l‟omopolimero (tL-dab)12  non lega un dA12 complementare. 
Inoltre, si è osservato che l‟introduzione di un monomero di dabPNA nella parte 
centrale o all‟ N-terminale di un filamento t12 di aegPNA ha portato ad oligomeri 
caratterizzati da una minore affinità di legame verso il DNA complementare rispetto 
ad un filamento interamente costituito da aegPNA. 
E‟ stata poi esplorata la capacità del nuovo omopolimero di ibridare l‟RNA (A12), ma 
anche in questo caso esperimenti CD hanno evidenziato che per il filamento (tL-dab)12 
non si ha formazione di una struttura duplex con il target complementare. 
A questo punto è stato sintetizzato il monomero tD-dab che è stato oligomerizzato 
all‟esamero  (tD-dab)6 utilizzando le stesse procedure illustrate per ottenere tL-dab.e 
l‟oligomero corrispondente (tL-dab)12 . Anche in questo caso attraverso studi CD e UV 
non si evidenzia capacità del (tD-dab)6 di legame verso DNA e RNA. Poichè  dabPNA 
basati su L- e D-DABA non legano acidi nucleici naturali, è stata esplorata la 
possibilità che nucleopeptidi complementari basati su D- o L-DABA si leghino fra 
loro. Questa capacità è di grande interesse per lo sviluppo di sistemi dendrimerici, 
come nuovi materiali, e anche per la realizzazione di nuovi strumenti diagnostici, 
come per esempio le sonde  molecolari, in analogia a quanto è stato già riportato per 
gli alanilPNA (Diederichsen et al.,1996). In particolare, questi analoghi, che non 
legano acidi nucleici naturali, come verificato nel caso dei dabPNA, ma hanno la 
capacità di legare se stessi in filamenti complementari con chiralità alternata e per 
tale motivo sono stati proposti come costituenti della porzione in duplex degli stem 
presenti nei molecular beacon, lasciando l‟oligonucleotide naturale nel loop della 
struttura a forcina (Figura 4).  
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Figura 4:  (a) filamento di L-alanilPNA; (b) molecular beacon con stem a base di 
alanilPNA. 
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Il vantaggio di utilizzare una molecola così strutturata risiede nel fatto che se la parte 
dello stem in doppia elica non riconoscesse target naturali, potrebbe aumentare la 
specificità della sonda nei confronti del target cellulare; in aggiunta la porzione dello 
stem conferirebbe una maggiore resistenza della sonda all‟attacco delle nucleasi. 
Per i nostri scopi sono state sintetizzate, utilizzando le stessa procedura sintetica 
illustrata nello Schema 1, i monomeri aL-dab e  aD-dab dove ovviamente per entrambe 
come base azotata carbossimetilata  si utilizza quella  adeninica e rispettivamente L- 
e il D-DABA come diamminoacido. 
Con i monomeri tL-dab, tD-dab, aL-dab e  aD-dab ottenuti si sono sintetizzati i seguenti 
sistemi oligomerici: 
 
- H-G-(aL-dab)6K-NH2;   
- H-G-(aL-dab)6K-NH2 ; 
- H-G-(tL-dab-tD-dab)3K-NH2 ; 
- H-G-(aL-dab-aD-dab)3K-NH2; 
- H-G-(tL-dab-tD-dab)3K-NH2; 
- H-G-(aL−dab-tD−dab)3K-NH2. 
 
A questo punto sono stati effettuati studi di ibridazione tra i  sistemi costituiti da: 
- filamenti con stessa chiralità : H-G-(aL-dab)6K-NH2  / H-G-(tL-dab)6K-NH2; 
- filamenti con opposta chiralità : H-G-(aL-dab)6K-NH2  / H-G-(tD-dab)6K-NH2; 
- un filamento con chiralità alternata e un filamento omochirale:  
H-G-(aL-dab)6K-NH2/H-G-(tL-dab-tD-dab)3K-NH2  
- filamenti con chiralità alternata: H-G-(aL-dab-aD-dab)3K-NH2/H-G-(tL-dab-tD-dab)3K-
NH2; 
- filamenti di oligomero autocomplementare: H-G-(aL−dab-tD−dab)3K-NH2. 
 
 
Dagli esperimenti CD e UV, si ha evidenza di legame nel caso di oligomeri con 
chiralità alternata a6D,L-dab/ t6D,L-dab, anche se la stabilità del complesso formato 
non è molto elevata (Tm 11°C).  
Inoltre, da studi preliminari di DLS relativi all‟oligomero autocomplentare H-G-(aL−dab-
tD−dab)3K-NH2 emerge che vi è la formazione di un aggragato multimerico per questo 
sistema.  
Questi risultati, insieme all‟alta stabilità in siero osservata per gli oligomeri basati sul 
DABA, suggeriscono  l‟utilizzo di polimeri di dabPNA nello sviluppo di nuovi 
nanomateriali o di nuovi strumenti biotecnologici per applicazioni biomediche e della 
bioingegneria.  
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Summary 
Aminoethylglycyl peptide nucleic acids (aegPNAs) emerged more than a decade ago 
as strong and specific DNA/RNA binding agents, triggering much research interest 
into the development of PNA based antisense/antigene therapeutics (Nielsen et al, 
1993 and Nielsen et al., 1994) or diagnostics (Carlsson et al., 1996) thanks to their 
remarkable properties. 
Many efforts have mainly been directed towards the refinement of aegPNA properties 
such as binding affinity to DNA/RNA, water solubility, discrimination between parallel 
and antiparallel binding modes and cellular uptake (Uhlmann et al, 1998). Different 
PNA modifications are widely described in the scientific literature, having met in 
some cases with success. 
The most explored PNA modifications regarded the aminoethylglycine backbone and 
the methylene carbonyl linker (1st generation modifications). In the 1st generation 
modifications the only tolerated substitution regards the α-position of the glycine. For 
example, substitution of the glycine with an alanine (D or L) resulted in a slightly 
lower binding affinity towards DNA. Introduction of a D-lysine resulted in a slight 
increase of Tm in the binding to DNA, while the L-isomer had the opposite effect. 
In addition, much work has been devoted to investigate various cyclic backbone-
based PNAs (Gangamani et al., 1999 e Kumar et al., 2000) (2nd generation 
modifications) with the goal of increasing the selectivity or strength of interaction with 
natural nucleic acids. This class of modifications, by connecting different parts of the 
PNA backbone, introduces conformational restrictions and stereocenters into the 
polymer which can present remarkable hybridization properties. Among these kind of 
modifications aminoprolyl PNA containing oligomers are very interesting. aegPNAs 
with a single aminoprolyl PNA unit at N-terminus showed discrimination of antiparallel 
vs parallel binding to DNA. Another class of interesting PNA analogues is based on a 
diaminoacid backbone carrying the nucleobase by means of an amidic bond to one 
amino group. In particular, it was recently reported that an oligo thymine PNA 
analogue based on D- or L-ornithine binds to RNA by forming triple helices (Sforza et 
al., 2002).  
In this context we report our investigation about novel chiral PNA analogues, 
focusing the attention not only to the synthetic strategies but also to the binding 
studies towards natural and artificial targets. 
The new analogue designed and realized is a chiral nucleo-γ-peptide, dabPNA, 
isomer of the aegPNA unit and characterized by a 2,4-diaminobutyric acid (DABA)-
based backbone carrying the carboxymethylated nucleobase on its α amino group. 
Differently from aegPNA monomers, dabPNA presents a shorter backbone (3C 
between the nitrogen atom and the carbonyl) and an enhanced distance between the 
nucleobase and the backbone, i.e. 3 atoms (1N+2C) instead of 2C in aegPNAs. 
Furthermore, in comparison with ornPNA that binds to RNA forming a stable triplex, 
daba-based PNA has a methylene group less in the backbone. 
To achieve dabPNA oligomers, the new monomers tL-dab, tD-dab, aL-dab and  aD-dab were 
synthesized in good yield using suitable protected building blocks and characterized 
by NMR and ESI-MS techniques.  
Initially, the homothymine oligomers (tL-dab)12 and (tD-dab)6 were synthesized, using a 
synthetic strategy that ensured the maintenance of chirality during the coupling steps, 
and tested for hybridization towards natural nucleic acids. No binding evidence with 
both DNA (dA12) and RNA (A12) was revealed by CD and UV experiments. 
Furthermore, the insertion of a single tL-dab unit in the middle or at N-terminus of a 
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homothymine aegPNA chain leads to a decreased binding efficiency to the target 
DNA in comparison to full aegPNA. 
Since dabPNAs based on L- and D-DABA don‟t bind natural nucleic acids, we 
explored the possibility that complementary nucleopeptides based on D or L-DABA 
could bind between themselves. This property would be interesting in order to 
develop novel DABA-based dendrimeric systems, as new materials, and also to 
realize new diagnostic tools, as for example new molecular beacon probe. To verify 
this interesting possibility, the monomers aL-dab and  aD-dab were oligomerized to the 
homoadenine hexamers (aL-dab)6 and (aD,L-dab)6. In order to find the correct 
combination of chirality suitable for obtaining the binding, also the  (tD,L-dab)6  oligomer 
were realized to perform the hybridization studies.  
From CD and UV experiments, binding evidence was revealed in the case of the 
complementary oligomers with alternate chirality, (aD,L-dab)6 and  (tD,L-dab)6, even if the 
stability of the complex formed was not so high (Tm 11°C).  
Furthermore, some interesting properties relative to the self-complementary oligomer 
(aL−dab-tD−dab)3 emerged from preliminary DLS experiments that evidenced the 
formation of multimeric aggregates for this system.  
These results, together with the high serum stability of the DABA-based oligomers, 
suggest further studies on dabPNAs as new self-recognizing bio-inspired polymers, 
with the potentiality to develop new nanomaterials or new biotechnological tools in 
bioengineering and biomedical applications. 
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1. Introduction 
 
Oligodeoxyribonucleotide (ODN)-like molecules have been widely investigated as 
therapeutic or diagnostic tools for their ability to bind natural nucleic acids with 
complementary base sequence, but recently also for the possibility to develop new 
selfassembling materials based on hydrogen-bond pairing to be used in 
bioengineering (nanosensor devices) and biomedical (hydrogels for drug delivery) 
fields. 
 
1.1  Oligonucleotides (ODN) for biotechnological applications 
 
The recognition of nitrogenous bases of nucleic acids is of fundamental importance in 
biological systems because it ensures the conservation of genetic information and its 
transfer in living systems. The hybridization in nucleic acids is based on hydrogen 
bonding of Watson-Crick type between the complementary nucleobases: A-T (A-U) 
and G-C. Based on this simple system of pairing, several research groups have 
developed systems based on DNA or similar in view of new therapeutic applications 
(antisense/antigen) and diagnostics, or for the development of new materials.  
An oligonucleotide is a fragment of DNA or RNA with a number of less than 100 
nucleotide residues. The oligodeoxynucleotides (ODN) can selectively recognize the 
genetic material of the cell (for example, whether genes or mRNA) or specific 
proteins such as DNA binding protein (DBP), interfering with their normal functioning 
and in some cases blocking it. Therefore it can be easily understood the importance 
of strategies based on the use of these molecules in pharmacological approaches, 
such as when the gene is modulated or blocked viral DNA, an oncogene, or another 
gene involved in major diseases. An ODN is able to take early in a selective manner 
compared to traditional drugs that target proteins (Gewirtz  et al., 1998) generally. 
The approach used is that antisense dell'ODN where the target is a messenger RNA 
(mRNA, Figure 1b). The theory of antisense oligonucleotides requires relatively small 
molecules, ie, synthetic ODN lengths ranging from 13 to 30 nucleotides, possess the 
specificity required, due to their mechanism of action based on the formation of a 
double helix structure by hydrogen bonding Watson-Crick with a stroke of mRNA 
chosen as a target. The formation of a duplex between the ODN el'mRNA causes the 
deactivation of the mRNA target and a block of translation in order to obtain the 
corresponding repression of protein synthesis. 
 
Figure 1 Schematic illustration of (a) Normal gene expression, (b) antisense 
inhibition, (c) Inhibition of antigen. 
11 
 
Following  the formation of the hybrid RNA may lose its function in two distinct ways. 
The first type of event is the hydrolysis of the RNA target itself, after its hybridization 
antisense all'oligonucleotide by RNase H, which is an enzyme that degrades the 
RNA strand of an RNA-DNA hybrid. In the second case it is possible that the 
formation of the hybrid would result in a steric hindrance preventing the binding of 
proteins important for RNA processing (splicing) and interfering with the assembly of 
the ribosomal unit or the sliding of the ribosome along the messenger, or again with 
the nucleus-cytoplasm transport of the messenger. Besides antisense approach was 
developed further promising therapeutic strategies based on synthetic ODN, 
including the strategy is important to recall antigen, the aptamers (Wu CC et al., 
2003), ribozymes (Qureshi et al., 2006) and RNA interference (Hannon, 2002).  
The strategy is designed to inactivate an antigen gene (Figure 1c). In this case, the 
ODN is designed to pair up in a stretch of complementary dsDNA genome, forming a 
triple-helical stretch. Dell' ODN action, which occurs only in nuclear, achieves the 
same result as the antisense strategy, but with lower doses of medication and 
increased biological activity, as in the cell there are only two copies of the gene 
compared the hundreds or thousands of copies of messenger or protein.  
The aptamers are an emerging class of molecules with promising diagnostic and 
therapeutic applications. They are oligomers of DNA or RNA capable of binding to 
certain proteins with high affinity and specificity based on their structural 
characteristics. It is in fact the structure of the oligo that allows the selective 
recognition of the target protein.  
The natural ribozymes are RNA molecules capable of hydrolyzing specific sequences 
recognized mRNA. Unlike other molecules “tails blockers" with stoichiometric 
mechanism of action, have the advantage of being molecules with catalytic activity, in 
fact, a ribozyme molecule can hydrolyze more than one mRNA. By inserting this 
construct into an expression vector, transformed cells can be induced to synthesize 
the ribozyme that hydrolyze much faster then the target mRNA.  
RNA interference is a form of post-transcriptional gene regulation mediated by a 
double-stranded RNA (post trascripional gene silencing or PTGS). In practice, a 
double-stranded RNA signals the degradation of complementary mRNA, and then 
encoded by the gene is silenced quell'mRNA. The dsRNA is recognized within the 
cell by RISC (RNA-induced silencing complex), a multimeric complex with 
endonuclease activity, which separates the two strands of this molecule, select the 
strand complementary mRNA targets and guide the interaction with the target will be 
degraded, in the case of perfect complementarity between the ssRNA and the 
messenger, or, if not complete complementarity, it will create a steric hindrance that 
prevents access of the ribosomal machinery for translation. Given their relative ease 
of synthesis and high sensitivity and specificity of the ODN play an important role in 
the field of molecular diagnostics in vitro (Demidov et al., 2003). 
The diagnostic applications of ODN include the most commonly used DNA chip (DNA 
microarray), PCR-based techniques, methods of in situ hybridization (FISH) and 
detection of single nucleotide polymorphisms (SNPs), the molecular beacon, and 
much more. In particular, the molecular beacon probe is based on a single-stranded 
oligonucleotide that forms a “hairpin structure” (stem and loop). The loop contains a 
sequence complementary to the sequence of the target and the portion of the stem 
consists of two complementary treatments that flank the loop. A fluorophore and 
quencher are linked covalently to the end of the probe: the molecular beacon probe 
gives no fluorescence if it is in the form stem-and-loop, with a fluorophore and 
quencher spatially close, as it becomes fluorescent when it hybridizes to the target 
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sequence (Figure 2). Obviously the length of the loop and the stem must be such that 
the formation of a more stable probe-target compared to the one formed by two 
sections of the stem. The molecular beacons are extremely specific, it can 
discriminate between target sequences that differ from each other for even a single 
nucleotide (Tan et al., 2000). 
 
 
 
 
 
Figure 2: Mechanism of action of a molecular beacon probe. 
 
 
Taking advantage of the four bases of DNA recognition in many chemists and 
physicists have turned their attention to building systems based on dendrimeric ODN 
to develop new nanomaterials (Seeman et al., 2003). In this way opens the chapter 
of biotechnology at the nanoscale, which combines biological molecules with 
chemical and physical principles and procedures to create nanoscale structures with 
specific properties and functions. The DNA molecule exhibits chemical, structural and 
electronic properties that make it suitable for the formation of nanomaterials, which 
find applications in many research fields ranging from molecular biology to chemistry, 
including materials science and physics course, to engineering mechanics and 
electronics. The microscopic size of the DNA molecule with a diameter of about 2 
nanometers, its quick pace propeller 3.4-3.6 nm and its ability to self-assemble to 
form large three-dimensional structures, size, shape and density well-defined are 
essential for the construction of nanoscale devices. For example, the conjugation of 
gold nanoparticles with DNA allowed the construction of self-assembling nanowires, 
which are characterized in terms of structural and electronic products, which were 
measured the size and resistivity (Figure 3) (Mbindyo  et al., 2001).There are two 
main approaches currently pursued in nanobiotechnology: one is a “bottom-up” 
approach where materials and devices are made starting from the molecular 
components that self-assemble through chemical bonds, using principles of 
molecular recognition and the other is the approach of “top-down", where nanoscale 
devices are made from materials from which macroscopic "cut" the nanostructures 
through a careful process control of miniaturization precisely at the atomic level. 
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Figure 3: (a) Conjugation of ODN modified with Nanogold ®, (b) TEM image of a 
DNA duplex conjugated to gold nanocrystals. 
 
 
1.1.a Limits on the use of natural ODN 
 
The use of synthetic ODN for the regulation of gene expression, although it seems a 
valid and rational, in fact, presents practical difficulties, due to the difficulty of 
penetration of cell membranes and the short half-life of these molecules (Calogero, 
1997).The cellular uptake problem stems from the fact that an oligonucleotide is by 
nature a polyanion, so do not have the ability to diffuse across cell membranes, 
consisting essentially of lipid structures.Today this problem seems less important, as 
the oligonucleotides can enter cells using active absorption mechanisms, mediated 
by receptors and channels on the cell surface. They can also be encapsulated within 
lipid particles called liposomes (cationic lipids) to improve the lipophilicity (Meyer et 
al., 1998), or can be conjugated to suitable carriers, exploiting the natural cellular 
uptake. In human serum, as well as in the cytoplasm of various cell systems, the 
nuclease responsible for rapid degradation of DNA and RNA, reducing the half-life in 
minutes. Consider also that only a process of hydrolysis could inactivate the oligo or 
even make it toxic. 
 
 
1.1.b  Oligodeoxyribonucleotide (ODN)-like molecules. 
 
To overcome the limitations just mentioned, over the years, many researches have 
been focused on the introduction of chemical modifications in the structure of the 
ODN, while preserving the ability of molecular recognition (Chen et al., 2005). 
In general, the features should have a similar synthetic oligonucleotides are: 
resistance to nucleases, good cellular uptake, high affinity for nucleic acid target, 
high binding specificity and low toxicity. 
Clearly, any deviation from the original structure implies the often unexpected 
consequences, leading to alterations in the ability to recognize the complementary 
strand in duplex or triplex stability of the complexes formed in recognition of certain 
enzymes or proteins. 
The possible sites of modification in an oligonucleotide can involve the sugar-
phosphate backbone and / or nucleobases (Figure 4). 
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Figure 4: Possible sites of modification of DNA. 
 
 
Amendments to the ODN can be grouped into three classes: 
1) modifications of the first generation, which include analogues with alterations at 
the level of the phosphate; 
2) changes in the second generation which have similar changes in blood sugar                                
(mainly in position 2 ' of ribose) or the heterocyclic bases; 
3) changes in third generation, which include analogues in which the changes relate 
to the ribose or the phosphodiester bond and also include molecules with a 
completely different place furanosic ring of sugar. 
The first generation of changes designed to make the most internucleotide linkages 
resistant to nucleases, the backbone phosphodiester concern and led to the 
synthesis of a wide variety of analogues such as phosphorothioates (Agrawal et al., 
1998) (a) and phosphorodithioate (b), methylphosphonates (Miller et al., 1991) (c) 
and hydroxymethylphosphonium (d), the  phosphodiester (s) and phosphoramidates 
(Agrawal et al., 1998) (f) (Figure 5). 
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Figure 5: First-generation antisense oligonucleotides: (a) phosphorothioate, (b) 
phosphorodithioate, (c) methylphosphonates, (d) hydroxymethylphosphonium (e) 
phosphodiester, (f) phosphoramidates. 
 
 
The phosphorothioate ODN, in which one of the oxygen does not bridge the 
phosphodiester bond is replaced by a sulfur atom, similar results are very promising 
as part of the antisense.  
The Vitravene ®, a phosphorothioate used in local treatment of cytomegalovirus 
retinitis (CMV) in patients with acquired immunodeficiency syndrome (AIDS) was the 
first drug based on antisense oligonucleotide approved by the FDA (Anderson et al., 
1998). 
The 2'-O-alchilribonucleotidi (Majlessi  et al., 1998) are similar to the second 
generation, derived from the RNA, in which the hydroxyl group 2 ' is etherified with an 
alkyl-group. Among the most representative are the 2‟-O-methoxy-ethyl 
ribonucleotides (Figure 6a) and 2'-O-methyl (Figure 6b). 
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Figure 6: Second-generation antisense oligonucleotides. 
 
 
These derivatives are comparable to the DNA from the viewpoint of chemical 
stability, are resistant to nucleases and, in particular, the resistance increases, as 
well as the lipophilicity, with increasing alkyl chain length. Given these positive 
features, the only disadvantage is that the 2'-O-methyl-RNA are not able to induce 
the enzymatic cleavage of mRNA target by RNase H. 
Among the analogues of the third generation Morpholino phosphoramidates (MP, 
Figure 7a) (Corey et al., 2001), peptide nucleic acids (PNA, Figure 7b) (Nielsen et al.,  
1991) and locked nucleic acids (LNA, Figure 7c) (Wahlestedt et al., 2000) are those 
which have aroused the most interest. 
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Figure 7: Similar ODN third generation: (a) MP, (b) PNA, (c) LNA. 
 
 
These compounds are essentially resistant to nucleases and keep a good affinity for 
their complementary target. 
In particular it has been demonstrated in vivo the potent knock-down of similar MPs, 
acting recognizing sequences within the target mRNA, resulting in a steric hindrance 
that prevents interaction with other molecular partners. Precisely for this reason 
many therapeutic compounds have been developed, one of which is directed against 
the oncogene c-myc, which is currently in phase I and phase II clinical trial, produced 
by AVI BioPharma (Portland, OR, USA). 
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The LNAs are a class of sugar analogues in which the ring is conformationally 
"locked" by a methylene bridge connecting carbon atoms 2' and 4'. The bridge locks 
the ribose conformation in the C3' endo (often found in the A form of DNA and RNA), 
this structural organization appears to be an important factor to ensure high affinity 
binding of these analogs with the natural nucleic acids, a thermal stability and high 
resistance to nucleases. 
It was shown that these analogues inhibit tumor growth in a xenograft model, using 
an effective concentration of LNA is five times lower than that found for the 
corresponding phosphorothioate analogue. 
Among the many similar oligonucleotide in the literature, peptide-nucleic acids (PNA), 
described for the first time in Nielsen et al. in 1991 have certainly enjoyed the most 
successful offering in both therapeutic and diagnostic prospects encouraging 
continuous development. 
 
 
1.2 Peptide nucleic acids (PNA) 
 
The PNAs are structural mimics of DNA, in which the sugar phosphate backbone is 
replaced by an entirely neutral and achiral polyamide backbone consisting of 
repeating units of N-(2-aminoethyl)glycine (aeg), joined by amide bond. 
Each of the four nucleobases, adenine, cytosine, guanine and thymine, is linked to 
the backbone through a methylene carbonyl linker. The skeleton pseudopeptide is 
designed so that the bases keep the distance between them that in natural DNA and 
are able to recognize the complementary bases, obeying the Watson-Crick bonding 
pattern (Uhlmann et al., 1998) (Figure 8). 
 
 
 
 
 
 
Figure 8: Comparison between the structure of a protein, and a duplex PNA / DNA. 
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Being achiral, the PNA binds to natural DNA and RNA in parallel or antiparallel 
(Figure 9), depending on whether the amino-terminal, respectively, PNA binds the 5' 
end or the 3' end of DNA between the  two antiparallel orientation is slightly preferred 
to the parallel, and its kinetics of formation is much faster than that of the complex 
parallel. 
 
 
Figure 9: Schematic representation of orientation that may have a duplex 
PNA: DNA. 
 
From numerous studies on these molecules is immediately revealed that the PNA 
specifically recognize complementary strands of DNA and RNA, and in particular, the 
PNA-DNA hybrids and PNA-RNA are more stable, respectively, for DNA-DNA and 
DNA RNA (due to less electrostatic repulsion), and also PNA-RNA duplex is more 
stable than the corresponding PNA-DNA duplex (Egholm et al., 1993). 
PNAs  with complementary sequences, also can hybridize with each other through 
the training Watson-Crick (W-C) hydrogen bonds highly specific, creating parallel or 
antiparallel duplex (preferred orientation), extremely stable (Eriksson et al., 1996). 
The PNA is able to adopt both conformations A and B when they bind, respectively, 
RNA and DNA, while the PNA-PNA duplex are structured in a particular 
conformation, called P-form, characterized by a helix tour of 18 base pairs larger than 
the forms A and B. 
 
 
 
 
Figure 10: The conformation of the PNA-nucleic acid complex. 
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The PNAs are to be chemically very stable: in fact, unlike DNA, which undergoes 
depurination when treated with strong acids, are completely stable. The only 
chemical instability of the PNA is due to the amino group to N-terminus. In particular, 
in basic conditions can be a slow transfer to the nucleobase acetyl-N-terminal amino 
group of the backbone (Figure 11a) or the loss of monomer through the N-terminal 
cyclization (Figure 11b). These secondary reactions can be avoided by protecting the 
amino group to the N terminal, for example, with a group acetile (Uhlmann et al., 
1998). 
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Figure 11: (a) N-acyl transfer reaction, (b) loss of the last residue N-terminal. 
 
 
The PNA are not susceptible to enzymatic degradation by nucleases and proteases. 
Are therefore very biostable both in human serum and in extracts cellulari (Uhlmann 
et al., 1998). 
The use of PNA has led to the development of numerous therapeutic applications. 
These polymers, in recognition of natural nucleic acids, can interfere in the processes 
of replication, transcription and translation device (Egholm et al., 1993). 
A PNA can be designed to recognize and bind complementary sequences of a 
double helix of DNA, thus interfering with its replication and transcription (strategy 
antigen) (Eriksson et al. ,1996). The PNA is able to bind dsDNA, forming different 
types of complexes, as shown in Figure 12. The way in which the NAP interacts with 
target DNA double-strand depends on the base composition of the sequence 
involved. In general, the NAP applies a strand invasion mechanism, which involves 
the displacement of a DNA strand in the duplex. Where in the sequence of the target 
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dsDNA is present homopurinic. Suddenly, the PNA will bind to form two main types 
of triplex structures (DNA)2-PNA (c) e (PNA)2-DNA (d). In the latter form a PNA 
strand of Watson-Crick interactions and the other interactions with the Hoogsteen 
strand of complementary DNA (Buchardt et al., 1993). 
 
 
a b c d
 
 
 
 
Figure 12: Representation of the mode of binding of a PNA and dsDNA. The PNA 
oligomers are shown in bold (a) Standard duplex invasion. (b) Double duplex 
invasion complex, very stable, but only possible with PNA containing modified 
nucleobases. (c) conventional triplex structure. (d) Triplex invasion by displacement 
of one strand of dsDNA. 
 
 
A PNA that targets the promoter region of a gene can form a stable PNA-DNA 
complex that does not provide access to its DNA polymerase. In vitro studies have 
shown that these complexes are capable of influencing the process of transcription in 
both prokaryotes and eukaryotes. 
Alternatively, a PNA can be designed to recognize and bind complementary 
sequences in mRNA (antisense strategy) (Nielsen et al., 1994). 
Generally, the effect of PNA as antisense agents is based inhibition of process of 
maturation, transport and translation of RNA in the cytoplasm by forming complexes 
that cause steric hindrance, preventing interactions with other molecules that 
regulate these processes. 
Even the PNA in diagnostics have made a significant contribution. PNA oligomers 
show high binding specificity with a complementary DNA (stringency), which means 
that the wrong pairing between bases are more destabilizing in the case of duplex 
PNA / DNA (as well as PNA / RNA) than in duplex DNA / DNA . 
Due to their high stringency in the recognition of natural target, they have been used 
successfully to detect the presence of gene mutations point, as in the case of the 
CFTR gene for cystic fibrosis (Nielsen et al., 1994) are still subject of study of many 
international research groups. 
In addition, aegPNAs have recently been proposed as hypothetical precursors of 
prebiotic systems based on RNA, which, as is now widely accepted, preceded the 
current world "DNA- RNA- proteins” (Nielsen et al., 1993 and Carlsson et al.,1996). 
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The implication of genetic aegPNA prebiotic evolution is supported by the following 
results: 
1)  aegPNA bind complementary RNA to form stable complexes; 
2)  can act as a template for the synthesis of RNA (transfer information from aegPNA         
to  RNA has been demonstrated experimentally); 
 3) the constituents of aegPNA, in particular N-(2-aminoethyl)glycine and 
carboxymethylated nucleobases, can be obtained under prebiotic experiments. 
However, the synthesis of the whole molecule of PNA in simulated prebiotic 
conditions has not yet been implemented, so that we can not draw definitive 
conclusions about the importance of aegPNA nell'abiogenesis. 
 
 
1.2.a Synthesis of PNA 
 
The synthesis of PNA can be performed in analogy to peptides (Merrifield 1986), with 
solid phase strategies making use of a solid support, e.g. a (methylbenzhydryl) 
amine polystyrene resin (Christensen et al. 1995; Pothukanuri et al. 2008; Lee et al. 
2007), and of Fmoc(9-fluorenylmethoxycarbonyl group)-protected PNA monomers in 
which the exocyclic amino groups of A, G and C  bear Bhoc(benzyhydryloxycarbonyl) 
protecting groups which are removed at the end of the synthesis by treatment with 
trifluoroacetic acid. The primary amino group in the monomer backbone can be 
deprotected from the Fmoc-group by treatment with 20% piperidine in DMF 
(dimethylformamide) at the end of each coupling step. After the synthesis is 
accomplished, the PNA can be cleaved from the resin by treatment with 
trifluoroacetic acid and m-cresol (4/1 v/v) and precipitated by cold diethyl ether. 
Subsequently, HPLC purification can be performed and pure PNA oligomers are 
characterized by mass spectrometry (Christensen et al. 1995). Taking into account 
the importance of the orthogonality of PNA synthesis with other chemistries, 
Pothukanuri et al. performed a thorough investigation of six types of protecting 
groups for the terminal nitrogen atom and five protecting groups for the nucleobases 
of PNA monomers (Pothukanuri et al. 2008). Furthermore, the synthesis of self-
activated PNA monomers as well as an efficient route to PNAs using a 
benzothiazole-2-sulfonyl group as an amine-protecting group and an acid-activating 
group were also reported by Lee et al.(2007). Since the synthesis of homothymine 
PNA segments, required for the construction of PNA-based triplex structures, is 
plagued by the occurrence of a significant amount of truncation products, Altenbrunn 
and Seitz investigated the use of novel allyl-protected thymine PNA monomers which 
provided significant improvements to the yields with the standard protocols used in 
the automated PNA synthesis (Altenbrunn and Seitz 2008). Interestingly, the 
synthesis of a Fmoc/Boc pseudoisocytosine monomer for peptide nucleic acid 
assembly was recently described by Hudson and Wojciechowski (2008). 
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 Figure 1.13: aegPNA protected monomers.   
 
 
1.3 Modifications PNA: Nucleopeptides. 
 
Besides the remarkable binding properties of aegPNAs, however, some drawbacks, 
such as low water solubility, poor cell permeability, costly precursors and also 
ambiguity in nucleic acids recognition (parallel/antiparallel) (Ray et al., 2000), are 
expected to be over come.  
Different PNA modifications are widely described in the scientific literature, having 
met in some cases with success. 
The type of changes reported in the literature aim to: 
 
1. To introduce chirality in an achiral molecule selectively in order to guide the 
direction parallel / antiparallel hybridization with target DNA; 
2. To produce molecules that have less conformational freedom in the backbone, 
pre-established structure in order to govern the hybridization to the target; 
3. Add a cationic functional groups directly into the backbone of the PNA, or ends 
N-and C-terminal to improve its solubility in water; 
4. Modular pairing between the nucleobases, by modifying or the methylene 
carbonyl  linker or the bases; 
5. Combining with the PNA molecules that act as carriers to optimize their entry 
into the cell. 
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The most explored PNA modifications regarded the aminoethylglycine backbone and 
the methylene carbonyl linker (1st generation modifications). 
Surely one of the most important consists in stretching the structure dell'aegPNA by 
the addition of a methylene group to the polyamide backbone or linker, such as in the 
case of PNA with repeating units of N-(2-aminoethyl)- β-alanine (Figure 15a), or PNA 
in which the nucleobases are linked through an ethylene bridge carbonyl (Figure 
15b). 
 
a b
 
 
 
 
Figure 15: PNA with (a) backbone of N-(2-aminoethyl)-β-alanine and (b) carbonyl 
linker ethylene. 
 
 
In the 1st generation, it was found, however, that changes in the first generation the 
only substitution tolerated focused on the α-position of glycine. 
For example, substitution of the glycine with an alanine (D or L) resulted in a slightly 
lower binding affinity towards DNA. 
Among the changes to the PNA of 2st generation, many works have been oriented to 
the design of molecules with a cyclic backbone (Kumar et al, 2002 and Gangamani et 
al., 1999). These types of changes, involving the connection of different portions of 
the skeleton of PNA, introduce conformational restrictions and / or resulting 
stereocenters in the polymer, giving interesting properties of hybridization. In this 
context, the PNA amminoprolil (ampPNA, Figure 16) were the compounds that have 
attracted most interest. 
 
B
N
N
H
O
O
B
N
N
H
O
O
 
B
N
N
H
O
O
aegPNA
* *
ampPNA
 
 
 
Figure 16: Comparison between aegPNA and ampPNA. 
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Oligomers formed entirely of monomers ampPNA however, showed no ability to 
target nucleotide natural hybridization.  Surprisingly, the polymer where the aegPNA 
monomers alternate with those of ampPNA showed DNA binding affinity higher than 
oligomer format entirely aegPNA. The aegPNA oligomers containing a single unit of 
the N-terminus amminoprolil PNA, have shown a remarkable ability to discriminate 
between the bond than parallel to antiparallel DNA. 
In particular, the possibility to discriminate between parallel/antiparallel binding 
modes is an important feature for a nucleotidic analogue to achieve the best 
specificity in the detection of complementary strands of natural targets. To introduce 
this favourable characteristic into PNAs, different approaches were reported in which 
aminoacidicmoieties, especially lysines or arginines, were added to the aegPNA 
ends (Ray et al., 2000 and Silvester et al., 2007). In this way the presence of the 
stereogenic centres allowed for improved binding mode discrimination, while the 
positive charge of the aminoacidic side chain favoured the solubility of the PNA 
oligomers. Furthermore, lysine units were also inserted in the aegPNA backbone in 
place of the glycine unit creating a chiral box inside the PNA oligomer (Sforza et al., 
2000). 
As can be seen, artificial nucleic acids illustrated, unlike the common aegPNA, 
whose backbone is pseudo-peptide, possess a peptide skeleton, they are referred to 
as nucleopeptides. 
This class of molecules, nucleobase-containing peptides, has gained a considerable 
attention in the scientific community for the possibility of achieving novel powerful 
molecules able to : 
(a) interact with natural nucleic acids; 
(b) form materials, in particular, molecular networks based on hydrogen-bonding 
schemes between complementary (or self-complementary) nucleopeptide 
strands. These networks are useful for complexation and release in cell genes 
and drugs. 
 
 
1.4 Diaminoacid-based nucleopeptides 
 
In 1996, two different research teams reported on nucleopeptides based on a chiral 
natural diaminoacid, i.e. ornithine (6a, Figure 6), which was functionalized with 
thymine nucleobase through a methyl carbonyl linker by using thymine acetic acid. 
More in detail, Lioy and Kessler prepared three chiral nucleopeptides by making use 
of both L- and D-ornithine nucleoamino acids by a Fmoc solid phase synthetic 
strategy (Lioy and Kessler 1996), whereas Petersen et al. reported the synthesis and 
the evaluation of the RNA-binding properties of a decamer based solely on the L-
enantiomer (Petersen et al. 1996). 
Subsequently, Korshunova et al. (1997) reported the design and the synthesis of 
several „„oligonucleopeptides‟‟, i.e. δ-nucleopeptides based on ornithine with an ethyl 
linker to the nucleobase (6b, Korshunova et al. 1997). Ornithine-containing δ-
nucleopeptides based on repeating unit 6a were also the object of researches 
performed by Inaki et al. (1998), which demonstrated by CD and NMR the presence 
of hydrogen-bonding between thymine and ornithine moieties (Inaki et al. 1998) in 
such nucleopeptides, and by van der Laan et al., who in the same year prepared 
several chirally-pure ornithine nucleopeptides (Van der Laan et al. 1998). Four years 
later Mandrugin et al. reported the synthesis of „„new hetero organic nucleopeptides‟‟, 
whose base sequence was complementary to specific viral mRNA regions 
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(Mandrugin et al. 2002). Such nucleopeptides were characterized by a δ–ornithine 
backbone, with some residues carrying also free amino groups in the linker to 
nucleobase (6c). 
 
 
 
 
Figure 6: Molecular representation of ornithine-based repeating units in some 
literature δ-nucleopeptides. 
 
 
In the same year a study by Sforza et al. demonstrated the need of modified coupling 
conditions to obtain by solid phase synthesis optically pure D- or L-ornithyl δ-peptides 
(based on 6a moieties) which presented novel binding characteristics towards nucleic 
acids, as they demonstrated by CD spectroscopy (Sforza et al., 2002). More in detail, 
the use of HATU as a coupling agent, and collidine (TMP) as a base, to be added in 
portions and without preactivation of the nucleoamino acid monomer, led to the 
lowest degree of epimerization, as reported by Corradini et al. (2001) for the 
synthesis of ornithine-containing nucleopeptides. It was reported that an oligo 
thymine PNA analogue based on D- or L-ornithine binds to RNA by forming triple 
helices (Sforza et al., 2002). 
In this context we report our investigation about novel chiral PNA analogues, 
focusing the attention not only to the synthetic strategies but also to the binding 
studies towards natural and non-natural targets. 
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2. Aim of the thesis 
 
In our research for the development of new ODN-like drugs or diagnostics and new 
materials, we set as its objective the realization and binding studies with natural and 
non natural targets of new  chiral nucleo-γ-peptide, dabPNA (2, Figure 17), isomer of 
the aegPNA unit (1, Figure 17) and characterized by a 2,4-diaminobutyric acid 
(DABA)-based backbone carrying the carboxymethylated nucleobase on its α amino 
group. 
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Figure 17:  Comparison between aegPNA(1), dabPNA (2), ornPNA(3). 
 
Differently from aegPNA monomers, dabPNA (2, Figure 17) presents a shorter 
backbone (3C between the nitrogen atom and the carbonyl) and an enhanced 
distance between the nucleobase and the backbone, i.e. 3 atoms (1N+2C) instead of 
2C in aegPNAs. Furthermore, in comparison with ornPNA (3) that binds to RNA 
forming a stable triplex, daba-based PNA has a methylene group less in the 
backbone.  
Our interest to the presented dabPNA arises from the possibility to obtain new 
molecules able to: 
1)bind  target  DNA and RNA for therapeutical or diagnostic applications; 
2) form molecular networks. 
DABA is a nonprotein amino acid found in the seeds and vegetative tissues of flatpea 
(Lathyrus sylvestris L.) distributed intracellularly in mature leaves with about 15% of 
the cellular DABA contained in chloroplasts and at least 75% in vacuoles(Foster et 
al., 1987).Interestingly, poly(2,4-diaminobutyric acid), (PDBA), was recently used in a 
novel nonviral cytokine gene delivery system, which makes use of PDBA instead of 
polylysine resulting in high transfection efficiency. 
In particular, in vivo antitumor effects of dendritic cell immunotherapy with poly(D,L-
2,4-diaminobutyric acid)-mediated intratumoral delivery of the interleukin-12 gene 
were evaluated with the conclusion that this system suppresses tumor growth 
significantly (Iwashita et al., 2005). 
Furthermore, this research was supported by the known stability of γ-peptides to 
enzymatic degradation and also by the proposal formulated by Meierhenrich et al. 
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(2004) DABA-based PNAs as prebiotic material in a primordial “PNA world” that 
would have preceded our present-day “two-polymer world”.  
This hypothesis followed the recovery of DABA and other diaminoacids  in the 
extraterrestrial soil of the Murchison meteorite (figure 18) together with the DNA 
purine and pyrimidine bases (Meierhenrich et al., 2004 and Nielsen et al., 1993). 
 
 
 
 
 
 
Figure 18: Fragment of the Murchison meteorite and some of the molecules found in 
the soil meteorite. 
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3. Results and discussion 
 
3.1 Synthesis and oligomerization of tL-dab monomer, and binding studies on  
(tL-dab)12 oligomer 
The synthetic strategy adopted to obtain the new monomer tL-dab is based on the 
conjugation of two building blocks, 2,4-diaminobutyrric acid adequately protected (A, 
Figure 3.1) and carboxymethylated nucleobase (B, Figure 3.1). 
 
 
 
 
 
Figure 3.1: Molecular basis for the synthesis of a monomer dabPNA: 
(A) 2,4-diaminobutirric acid protected  and (B) carboxymethylated nucleobase. 
 
 
The L-enantiomer of the natural diaminobutyric acid, was chosen, as starting material 
for the synthesis of the new monomer, in analogy to the L-ornithine-based PNAs, 
proposed by Petersen et al. (1996). 
In particular, the thymine containing monomer was synthesised starting from the 
commercially available Boc-(L)-DAB(Fmoc)-OH diaminoacid (1, Scheme 1). In the 
first synthetic step the Boc group was selectively removed with trifluoroacetic acid 
(TFA) to give the free amino group in α-position. The obtained product 2, 
characterized by 1H NMR and LC-ESIMS, was coupled with the thymine-1-acetic acid 
using HATU/DIEA/TMP as activating system in DMF leading to the compound 4 
(Figure 3.1) in 72 % yield. 
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Scheme 1:  Synthesis of tL-dab monomer. 
 
The Fmoc-protected monomer 4 was purified by precipitations and  characterized by 
1H/13C NMR and LC-ESIMS, shown in Figure 3.2.  
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Figure 3.2:  LC-ESIMS of tL-dab monomer. 
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The new monomer 4 was oligomerized manually on solid phase to the corresponding 
dabPNA dodecamer (5, Scheme 2) as showed in scheme 2. 
The synthetic substrate used was polystyrene Rink amide-MBHA resin (Figure 3.3) 
as a linker containing a derivative of benzidrilammina (MBHA) and having a cross-
linking of divinylbenzene (DVB, 1%). 
 
 
 
Figure 3.3: Rink amide-MBHA polystyrene resin. 
 
This support was initially treated with a solution of 20% piperidine in DMF to leave 
the protection of Fmoc amino functions. 
Subsequently, the deprotected support was reacted with a unit of lysine, sull'ammino-
protected side-chain group with the Boc group and the one linked to Cα with the 
Fmoc group. 
The reaction is being done in anhydrous DMF in the presence of PyBop/DIPEA, such 
as activating the carboxyl function of lysine against nucleophilic attack by the free -
NH2 group on the resin (Scheme 2). Any remaining free amino groups on solid 
support were blocked with a solution of acetic anhydride / DIPEA (20 / 5, v / v) in 
DMF. The yield of incorporation of lysine on the solid support was calculated by UV 
spectroscopy (UV Fmoc test). 
On the resin, so functionalized, is assembled the dabPNA dodecamer (5, Table 1) 
using for coupling HATU / TMP as activating system in NMP / DMF (1:4, v / v), as 
shown in Scheme 2.  
The choice of activator for the amidation of a carboxyl group having a chiral carbon in 
α is very critical because of the possibility of loss of chirality. In particular, since the 
racemization is promoted by deprotonation of the carboxylic group, the choice of the 
base, the activator, and pre-activation time points are essential to minimize this 
problem. In analogy to the synthetic strategy adopted for the coupling of L-ornithine, 
which is given to only 4% of epimerisation, we used for the coupling of the new 
monomer tL-dab, the weak base TMP, added in four aliquots over 1h and the activator  
HATU, without the pre-activation (Corradini et al., 2001). 
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Scheme 2: Synthesis of H-G-(tL-dab)12K-NH2 oligomer. 
 
 
The manual synthesis of the oligomer 5 allowed us to check, by UV Fmoc test, the 
coupling efficiency which was high in the first six steps (about 96%) and decreased 
gradually from 96% to 70% in the last six steps, probably because of the enhanced 
aggregation tendency of the increasing homo thymine chain. L-lysine and glycine 
residues were incorporated in the strand at C and N termini, respectively, to improve 
the solubility of the homo thymine polymer (overall yield: 24%). 
After cleavage and deprotection, the oligomer 5 was purified by semipreparative RP-
HPLC, and successively characterized by LC-ESIMS (Figure 3.4).  
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Figure 3.4 : LC-ESI MS of H-G-(tL-dab)12K-NH2 oligomer. 
A t12 aegPNA (6, Table 1) was synthesised as reference oligomer for the binding 
studies. The synthesis of 6 was realized on the automatic synthesizer showed in 
Figure 3.5 using standard 2 µmol scale protocol and the commercial PNA monomers 
(Figure 1.13). Overall yield of  6 was only of 18 % probably for aggregation problems 
concerning the homothymine sequence and enhanced by the automatic flow through 
synthesis.  
 
                             
 
Figure 3.5: ABI / Perceptive Biosystems Expedite model 8909 
 
Furthermore, other two dodecamer (7 and 8, Table 1), both carrying a single  tL-dab 
unit at N-terminal and central position of the aegPNA chain, respectively, were 
synthesized in order to explore the influence of the new DABA-based monomer on 
the aegPNA binding ability.  
33 
 
These oligomers were assembled on automatic synthesizer using a standard 2 µmol 
scale protocol for the aegPNA part and with manual single insertion of tL-dab monomer 
using the protocol described for 5. The overall yields of 7 and 8 were 18% and 19%, 
respectively. After deprotection and detachment from the solid support with TFA, 
oligomer 6-8 were purified by RP-HPLC and characterized by LC-ESIMS. 
All the dodecamers, 5-8, were quantified by UV spectroscopy, measuring the 260 nm 
absorbance at 85 °C, due to the tendency of PNA to aggregate at room temperature, 
and calculating the overall  extinction coefficient (ε260) as the sum of the ε260 of the 
PNA thymine monomer. 
For each oligomer the CD spectrum was registered. As expected, a solution of the 
aegPNA 6 didn‟t show a significant CD spectrum. In contrast, CD  spectrum of the 
oligomer H-G-(tL-dab)12K-NH2, due to its chiral nature, showed CD signal. In particular, 
a negative band in the 260-290 nm region was detected (Figure 3.5a) analogously to 
the spectrum reported in literature for the PNA analogue based on the L-ornithine, H-
(tL-orn)10K-NH2, that presents a negative band in the same region (Figure 3.5b). The 
chiral tL-dab unit in 7 and 8 seemed to be not sufficient to these oligomers to show a 
significant CD signal. 
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Figura 3.6: (a) CD spectrum of oligomer 5 H-G-(tL-dab)12K-NH2 (4 µM) in 10 mM, 
phosphate buffer pH 7.5; (b) CD spectra of oligomers H-(tL-orn)10K-NH2 (L, 10 µM) e 
H-(tD-orn)10K-NH2 (D, 10 µM)  in 10 mM phosphate buffer, 100 mM NaCl, 0.1M EDTA, 
pH 7. 
 
Successively, the ability of the new oligomer (tL-dab)12 to bind natural nucleic acids 
was evaluated by CD experiments, using a Tandem cell, constituted from two 
separated reservoir communicating just by the upper part of the cell, in which  two 
solutions, initially separated, come in contact only after mixing by turning upside 
down the cell (Figura 3.6). 
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Figure 3.6 Hellma Tandem mix cell. 
 
 
Initially, we considered a DNA strand complementary to the PNA dodecamers (dA12): 
a solution of dA12 in phosphate buffer was kept in one of the Tandem cell reservoir (1 
mL), while oligomer 5, in the same buffer conditions, was in the other one.  
CD spectrum from 200 to 320 nm, corresponding to the “sum” spectrum of the 
separated strands, was registered. Successively the cell was turned upside down to 
allow the mixing of the two samples and again a CD spectrum was recorded. As 
shown in Figure 3.7a,  since the “sum” and “mix” CD spectra were almost the same, 
no binding evidence was revealed, even recording CD spectra of the “mix” sample at 
different time (10 min, 30 min, 1 h, 2 h, 3 h, 24 h), performing a kinetic experiment. 
Furthermore, also adding one equivalent more of oligomer 5, in a 2:1 total ratio of (tL-
dab)12/dA12, in order to verify the possibility to form a triple helix complex, the binding 
was not detected.As positive reference, the aforementioned CD experiment was also 
performed between  the aegPNA 6 and dA12, obtaining the spectra reported in Figure 
3.7b: in this case a clear evidence of the binding was detected. 
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Figura 3.7: Sum (red) and Mix (blue) CD spectra of (a)  (tL-Dab)12 6/dA12 H-G-(tL-
dab)12K-NH2 4 µM and dA12 4µM in 10 mM phosphate buffer of (b) t12 PNA 7/dA12.  
 
Furthermore, also from UV melting experiment on the solution of 5 and dA12, 
correctly annealed, no binding was revealed, as shown in Figure 3.8 the melting 
curve of H-G-(tL-dab)12-K-NH2/dA12  was a drift (red line). 
In order to study the effect of the single dabPNA insertion on the ability of aegPNA 
strands to bind complementary DNA, UV melting experiments on annealed samples 
containing dA12 and, respectively, oligomers 6, 7 and 8, were performed. Overlapped 
melting curves are shown in Figure 3.8 and the corresponding Tm values are 
summarized in Table 1. From the melting data it was clear that the insertion of tL-dab 
monomer in the middle (oligomer 8) or at N terminus (oligomer 7) of the 
homothymine aegPNA chain leads to a decreased binding efficiency to the target 
DNA in comparison to aegPNA 6. 
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Sequences 
Tm (°C) 
 0.5 
H-G-(tL-dab)12-K-NH2/dA12                                                           (5) - 
H-G-t12-K-NH2/dA12                                                                    (6) 86.2 
H-G-tL-dabt11-K-NH2/dA12                                                             (7) 84.8 
H-G-t6tL-dabt5-K-NH2/dA12                                                           (8) 72.0 
 
 
Table 1 Homo thymine sequences synthetized. 
 
 
 
Figure 3.8:  Melting curves of (5) H-G-(tL-dab)12-K-NH2/dA12, (6) H-G-t12-K-NH2/dA12, 
(7) H-G-tL-dabt11-K-NH2/dA12, (8) H-G-t6tL-dabt5-K-NH2/dA12 
 
In addition, the ability of the H-G-(tL-dab)12K-NH2 oligomer to hybridise a 
complementary strand of RNA (A12) was explored. Even in this case, from the binding 
experiment with the tandem cell (Figura 3.9a), as well as from the kinetic CD 
experiment, no binding evidence was revealed. 
As reference, the same experiment on the RNA A12 was performed with the aegPNA 
strand (6) and, as expected, in this case the “sum” and “mix  CD spectra resulted 
different, clear evidence of binding (Figura 3.9b). 
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Figure 3.9: sum (red) and Mix (blue) CD spectra of (a) H-G-(tL-dab)12K-NH2 4 µM and 
A12 RNA 4µM in 10 mM phosphate buffer and (b) t12 7/A12. 
 
On the basis of these findings we concluded  that L-dabPNAs based oligomers were 
not able to bind natural nucleic acids. 
 
3.2 Synthesis and oligomerization of tD-dab monomer, and binding studies on 
(tD-dab)6 oligomer 
Since the PNA oligomer based on L-DABA don‟t bind natural nucleic acids and 
considering that  different stereoisomers have different ability to adopt the 
conformation required to bind DNA or RNA, we thus explore the hybridization of the 
D-DABA-based nucleopeptides to nucleic acid targets. Nevertheless,  in this way we 
continue our investigation on  the hypothized prebiotic role of dabPNAs, after the 
recovery of  both L and D-DABA enantiomers in meteoritic soil (Meierhenrich et al., 
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2004). Our interest was successively devoted to the realization of the enantiomeric  
tD-dab monomer, starting from the commercial Boc-(D)-DAB(Fmoc)-OH (Scheme 3).  
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Scheme 3 Synthesis of tD-dab monomer. 
The tD-dab monomer 9, purified by RP-HPLC and characterized by NMR and LC-ESI 
MS, was oligomerized manually on solid phase (Scheme 4) to the corresponding H-
G-(tD-dab)6K-NH2  (10) following the same synthetic procedure used for the obtainment 
of oligomer 5.  
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Scheme 4 Synthesis of H-G-(tD-dab)6K-NH2 oligomer. 
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After cleavage and deprotection, homopolymer 10 was purified by semipreparative 
RP-HPLC on a C18 column, and successively characterized by LC-ESIMS (Figure 
3.10). 
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Figure 3.10 LC-ESIMS of H-G-(tD-dab)6K-NH2 homopolymer . 
 
CD spectrum of single strand H-G-(tD-dab)6K-NH2 (10), depicted in Figure 3.11a (blu 
line), showed a mirror image relationship relative to the enantiomer H-G-(tL-dab)12K-
NH2  5 (red line, Figure 3.11a), in analogy to the CD spectra reported in literature by 
Sforza et al.(2002) for the L- and D-ornPNAs H-(torn)10K-NH2, showed in Figure 
3.11b. 
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Figure 3.11 a) Mirror-image relationship between H-G-(tL-dab)12-K-NH2 (red line) and 
H-G-(tD-dab)6K-NH2 (blu line), 4 uM, 10 mM Pi, 10 °C; b) H-(tL-orn)10K-NH2 (L, 10 µM) e 
H-(tD-orn)10K-NH2 (D, 10 µM)  in 10 mM phosphate, 100 mM NaCl, 0.1M EDTA, pH 7.  
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Furthermore, we performed CD experiments to verify the ability of H-G-(tD-dab)6K-NH2 
to bind DNA and RNA (dA12/A12) using the “Tandem cell”. No difference between the 
sum CD spectrum, obtained before mixing the two components, and the complex CD 
spectrum, recorded after the mixing, was revealed for oligomer 10  with both DNA 
and RNA. The CD spectra remained almost the same also at different times by 
performing kinetic CD studies, or adding another equivalent of H-G-(tD-dab)6K-NH2 to 
the solution obtaining a 2:1  final ratio of (tD-dab)6/dA12 to verify the possibility to form 
triple helix. In addition UV thermal experiments of the annealed mixture  confirmed 
the absence of any significant H-G-(tD-dab)6K-NH2 /DNA(RNA) interaction, showing 
little drift curves. 
3.3 Synthesis and oligomerization of aL-dab and aD-dab monomers, and binding 
studies 
Since dabPNAs based on L- and D-DABA don‟t bind natural nucleic acids, we 
explored the possibility that complementary nucleopeptides based on D or L-DABA 
could bind between themselves. 
This property would be interesting in order to develop novel DABA-based 
dendrimeric systems, as new materials, and also to realize new diagnostic tools, as 
for example new molecular beacon probe. 
This idea is based on some scientific studies reported in the literature concerning 
alanylPNA (Figure 3.12 a). 
In particular, it was recently demonstrated that these analogues of PNA, whose 
backbone is composed of units of aminoacid L-alanyne that is grafted methylene-
nucleobase, while not natural binding target, are able to hybridize with themselves 
and are therefore been proposed as constituents of the duplex portion of the stem 
found in molecular beacons (Figure 3.12 b) are useful diagnostic tools for the 
analysis (detection) of target nucleotide sequences as well as for the detection of 
mutations (Diederichsen, U. et al.,1996).  
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Figure 3.12: : (A) single strand of L-alanylPNA, (b) molecular beacons with stem-
based alanylPNA. 
Similarly, one might think, if the dabPNA itself to a hybrid system like the one shown 
in Figure 3.13 for dabPNA 
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Figure 3.13: molecular beacon with dabPNA-based stem. 
 
To verify this interesting possibility, homoadenine and homothymine hexamers based 
on L- and D-DABA were realized in order to find, if possible, the correct combination 
of chirality suitable for obtaining the binding.  
In particular, we obtained and studied the following systems: 
  strands of the same chirality: H-G-(aL-dab)6K-NH2  / H-G-(tL-dab)6K-NH2; 
 strands of opposite chirality: H-G-(aL-dab)6K-NH2  / H-G-(tD-dab)6K-NH2; 
 an alternating chirality strand and a homochiral strand: 
H-G-(aL-dab)6K-NH2/H-G-(tL-dab-tD-dab)3K-NH2  
 two alternating chirality strands: H-G-(aL-dab-aD-dab)3K-NH2/H-G-(tL-dab-tD-dab)3K-
NH2; 
 two alternating chirality strands: H-G-(aL-dab-tD-dab)3K-NH2/ H-G-(aL-dab-tD-dab)3K-
NH2. 
With the previously synthesized tL-dab and tD-dab monomers, we initially realized the 
sequences H-G-(tL-dab)6K-NH2 (11) and H-G-(tL-dab-tD-dab)3K-NH2 (12), following the 
same synthetic procedure for 5. 
In order to assemble the poliadenine sequences, the new aL-dab and aD-dab monomers 
were synthesized, by reacting L- and D-Boc-DAB(Fmoc)-OH (1 and 1’), respectively, 
with  Bhoc-protected carboxy methylated adenine. (Scheme 5). 
 
OH
FmocHN
NH
2
O
NN
N
N
NHBhoc
OH
FmocHN
NH
O
ONN
N
N
NHBhoc
O
OH
OH
FmocHN
NHBhoc
O
Boc-(D or L)-DABA(Fmoc)OH
12, 12'
HATU (1.9eq)/DIEA
(2.6 eq)/ TMP (2.6 eq)
in DMF, 2h, r.t. (51%)
(2 eq)
TFA/DCM/H2O
     4.5:4.5 :1
50 °C, 1h (90%)
aL-dab, aD-dab
1, 1' 2, 2'
 
 
 
Scheme 5: Synthesis of aL-dab / aD-dab monomers. 
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The Fmoc-protected monomers (12 and 12’) synthesized,  were purified by RP-HPLC 
without TFA in the eluents, to avoid the loss of the acid labile Bhoc protecting group. 
aL-dab and aD-dab were characterized by 
1H /13C-NMR and LC-ESI MS (Figure 3.14). 
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Figure 3.14: LC-ESI MS profile of aL-dab monomer. 
 
The new chiral monomers aL-dab and aD-dab were used to synthetize H-G-(aL-dab)6K-
NH2 13, and H-G-(aL-dab-aD-dab)3K-NH2 14, with alternate chirality, following the same 
manual synthetic protocol used for all the previous syntheses to minimize 
racemization problems.  
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Scheme 6: Synthesis of polyadenine DABA-based oligomers. 
 
The coupling efficiency for the synthesis of 13 and 14, checked by UV Fmoc test, 
was on average around 70% in the first five synthetic steps and decreased rapidly in 
the last ones, giving an overall yields of 16% (13) and 18% (14). 
After cleavage and deprotection, the oligomers were purified by semipreparative RP-
HPLC, and successively characterized by LC-ESIMS, which confirmed the identity of 
the products. The LC-ESIMS profile of the new oligomer 11 and 13 is reported in 
Figure 3.15 as an example. 
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Figure 3.15: LC-ESI MS of H-G-(tL-dab)6K-NH2 (11) and H-G-(aL-dab)6K-NH2 (13)   
 
All the dabPNA hexamers were quantified by UV spectroscopy using the molar 
extinction coefficients (ε260) of the aegPNA monomers, and measuring the A260 at 85 
°C. 
Oligomer 13, due to its chiral nature, showed CD signal, as evidenced by its CD 
spectrum reported in Figure 3.16 (blue line). CD experiments revealed that the 
spectrum of (aL-dab)6 showed the same trend as that of homo polymer having  the 
same chirality (tL-dab)12 (red line, Figure 3.16 b), with a band shift of the minimum 
between 250-300 nm from 276 nm of (tL-dab)12 to 266 nm because of the different 
chromophores. 
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Figure 3.16 a) Overlapped CD spectra of (aL-dab)6 (blue line)and (tL-dab)12 (red line), 8 
µM in 10 mM phosphate buffer, pH 7.5; b)  Overlapped CD spectra of (aL-dab-aD-dab)3 
(blue line) and (tL-dab-tD-dab)3 (red line), 4 µM in 10 mM phosphate buffer, pH 7.5. 
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In addition, by comparing the CD spectra of the alternate oligomers (aL-dab- aD-dab)3 
and (tL-dab- tD-dab)3, a positive band between 260-320 nm was revealed, with the 
maxima centred at 274 nm, in the case of (tL-dab- tD-dab)3, and  at 284 nm, in the case 
of (aL-dab-aD-dab)3  (Figure 3.16b). 
The presence of clear CD signals for all oligomers suggested a structural 
preorganization of the chiral strands, confirmed by the temperature-dependent CD 
profiles (data not shown). 
CD hybridization studies were performed with tandem cell on H-G-(aL-dab)6K-NH2 /(tL-
dab)6: no significant binding evidence was revealed in this case. Indeed only little 
changes are recorded for the sum and mix spectra relative to this complex (Figure 
3.17). 
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Figure 3.17: Red sum of (aL-dab)6/ (tL-dab)6, Blue mix of (aL-dab)6/ (tL-dab)6 (4 µM each 
strand in 10 mM phosphate buffer, pH 7.5) 
 
Other CD experiments were carried out on the following systems: (aL-dab)6/ (tD-dab)6 ,         
(aL-dab)6/(tL-dab-tD-dab)3 and (aL-dab-aD-dab)3/(tL-dab-tD-dab)3. In the first case, no binding 
evidence was revealed, while in the second one, a little difference between the sum 
spectra (red line) and the mix (blue line) was observed (Figure 3.18), suggesting a 
possible hybridization between the strand with alternate chirality and homochiral 
oligomer. However, this finding was not supported by the UV melting experiment on 
the annealed strands: drift curve was recorded for this system, suggesting a possible 
transition at a temperature below 5°C (data not shown).  
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Figure 3.18: Red sum and blue mix (aL-dab)6/(tL-dab-tD-dab)3, (4 µM each strand in 10 
mM phosphate buffer, pH 7.5). 
 
In the case of (aL-dab- aD-dab)3/(tL-dab-tD-dab)3, CD measurements with tandem cell 
revealed a difference between the sum and mix spectra (Figure 3.20), which, in this 
case, was confirmed also by the UV thermal denaturation curve (Figure 3.21): 
indeed, a transition phase at 11 °C was detected. 
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Figure 3.20: Red sum and blue mix of (aL-dab- aD-dab)3/(tL-dab-tD-dab)3 ,(4μM each strand  
in 10 mM phosphate buffer,pH 7.5). 
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Figure 3.21:  UV melting of  (aL-dab- aD-dab)3/(tL-dab-tD-dab)3 2 μM each strand, in 10 mM 
phosphate buffer, pH 7.5). 
 
Also the self-pairing strand [H-G-(aL−dab-tD−dab)3-K-NH2](15), forming palindromic 
complex with complementary sequences, which showed the CD spectrum reported in 
Figure 3.22, revealed a transition phase in the UV-melting curve (Figure 3.23) at 22 
°C, confirming the binding between dabPNA strands of alternating chirality. 
 
 
Figure 3.22: CD spectra in 10 mM phosphate buffer (pH 7.5), 10 ◦C, 1-cm path 
length cell, of 4 μM (aL−dab-tD−dab)3. 
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Figure 3.23: UV-melting experiments of the self-pairing strand (aL−dab-tD−dab)3; (2 
μM each strand, in 10 mM phosphate buffer, pH 7.5) 
 
 
The sigmoidal profile of the UV-melting curves suggested the formation of complexes 
based on cooperative hydrogen bonds and base stacking. The processes were 
reversible and the pairing was completed in about 9 °C (18min at 0.5°C min−1) for 
system (aL-dab- aD-dab)3/(tL-dab-tD-dab)3 and 18 °C (36 min at 0.5 °Cmin
−1) for system 
(aL−dab-tD−dab)3. A further analysis of the melting behavior relative to alternating 
chirality systems((aL-dab- aD-dab)3/(tL-dab-tD-dab)3 and (aL−dab-tD−dab)3) revealed very 
substantial changes in the Tm  as a function of the concentration only for the self-
assembling system (aL−dab-tD−dab)3. Thus, for (aL−dab-tD−dab)3 the formation of 
structures held together by an intricate network of hydrogen bonds based on a 
stoichiometry of more than 1 : 1 should be considered.  
This hypothesis was supported by preliminary experiments of DLS that revealed for 
nucleopeptide (aL−dab-tD−dab)3 (100 μM in 10 mM phosphate buffer, pH 7.5), the 
formation of multimeric aggregates with an molecular weight (MW) ranging between 
1.6 × 104 and 4.5 × 105 kDa (with hydrodynamic radii, Rh, comprised between 109 
and 634 nm at 16 ◦C), and between 1.7 × 103 and 4.5 × 104 kDa at 20 °C (Rh 
reduced to 34–203 nm) (Figure 3.24).  
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Figure 3.24: Dynamic light-scattering experiments on the self-complementary 
dabPNA oligomer (aL−dab-tD−dab)3. 
 
 
 
Further investigations on the viscoelastic properties of system (aL−dab-tD−dab)3 are 
required to elucidate its bent to form hydrogels; moreover, NMR and X-ray 
experiments on both (aL−dab-tD−dab)3 and (aL-dab- aD-dab)3/(tL-dab-tD-dab)3 complexes are 
necessary to establish the orientation of the strands (parallel/antiparallel) and 
whether the Watson–Crick or Hoogsteen pairing is involved. In this frame, large-scale 
synthesis of oligomers (aL-dab- aD-dab)3 , (tL-dab-tD-dab)3 and (aL−dab-tD−dab)3 are in 
progress by our research group. In addition, we are going to synthesize also the C 
and G dabPNA monomers to assemble mixed sequence and different length 
oligomers. The binding properties of dabPNAs could be explained by comparing with 
the pairing properties of alanylPNAs containing an amino acid backbone with 
alternating configuration (Diederichsen et al, 1996). In analogy to alanylPNAs, which 
have a backbone differing from dabPNA for two C atoms, we expected for the γ -
peptide backbone of dabPNA an anti-periplanar orientation of the α-amino group and 
thus of the nucleobases. When L- and D-configuration is alternate in the backbone, 
the nucleobases should be orientated in syn-periplanar geometry. Finally, serum 
stability assays, performed by HPLC, showed that dabPNA (aL−dab-tD−dab)3 had a half-
life greater than 48 h (Figure 3.25); even if a good stability to enzymatic degradation 
is a fundamental characteristic in view of potential bioengineering and biomedical 
applications of dabPNAs, it will be necessary to study the toxicity of these 
compounds. 
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Figure 3.25: Serum stability assay on dabPNA (aL−dab-tD−dab)3 performed by 
HPLC. 
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4. Conclusions 
 
In conclusion, during the period of research done by the candidate in the PhD 
program, was designed and realized chiral nucleo-γ-peptides, dabPNAs, isomer of 
the aegPNAs and characterized by a 2,4-diaminobutyric acid (DABA)-based 
backbone carrying the carboxymethylated nucleobase on its α amino group. Our 
interest to dabPNAs arises, besides from the obtainment of new molecules for 
potential therapeutic and diagnostic applications, also from the possibility to explore 
their involvement in the prebiotic world, as recently proposed by Meierhenrich et al. 
(2004). This proposal followed the recovery of DABA in the extraterrestrial soil of the 
Murchison meteorite together with the molecular DNA constituent purine and 
pyrimidine bases, and other diaminoacids (Meierhenrich et al., 2004). 
In order to realize the chiral dabPNA oligomers, the new monomers tL-dab, tD-dab, aL-dab 
and  aD-dab were synthesized in good yield using suitable protected building blocks 
and characterized by NMR and ESI-MS techniques. 
Initially, the homothymine oligomers (tL-dab)12 and (tD-dab)6  were synthesized, using a 
synthetic strategy that ensured the maintenance of chirality during the coupling steps, 
and tested for hybridization towards natural nucleic acids. No binding evidence with 
both DNA (dA12) and RNA (A12) was revealed by CD and UV experiments. 
Furthermore, the insertion of a single tL-dab unit in the middle or at N terminus of a 
homothymine aegPNA chain leads to a decreased binding efficiency to the target 
DNA in comparison to full aegPNA. 
Since dabPNAs based on L- and D-DABA don‟t bind natural nucleic acids, we 
explored the possibility that complementary nucleopeptides based on D or L-DABA 
could bind between themselves. This property would be interesting in order to 
develop novel DABA-based dendrimeric systems, as new materials, and also to 
realize new diagnostic tools, as for example new molecular beacon probe. To verify 
this interesting possibility, the monomers aL-dab and  aD-dab were oligomerized to the 
homoadenine hexamers (aL-dab)6 and (aD,L-dab)6.  
In order to find the correct combination of chirality suitable for obtaining the binding, 
also the (tD,L-dab)6 oligomer was realized to perform the hybridization studies.  From 
CD and UV experiments, binding evidence was revealed in the case of the 
complementary oligomers with alternate chirality, (aD,L-dab)6  and  (tD,L-dab)6, even if the 
stability of the complex formed was not so high (Tm 11°C).  
Furthermore, some interesting properties relative to the self-complementary oligomer 
(aL−dab-tD−dab)3 emerged from preliminary DLS experiments that evidenced the 
formation of multimeric aggregates for this system.  
These results, together with the high serum stability of the DABA-based oligomers, 
suggest further studies on dabPNAs as new self-recognizing bio-inspired polymers, 
with the potentiality to develop new nanomaterials or new biotechnological tools in 
bioengineering and biomedical applications. 
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5. Experimental section 
 
5.1 Materials 
Fmoc-Gly-OH, HATU, Fmoc-Lys(Boc)-OH, and PyBOP were purchased from 
Novabiochem. Anhydroscan DMF and NMP were from LabScan. Piperidine was from 
Biosolve. Solvents for HPLC and Ac2O were from Reidel-de Ha¨en. TFA, Rink-amide 
resin, and TCH2COOH were from Fluka. [N6-(benzhydryloxycarbonyl)-adenine-9-yl] 
acetic acid was purchased from ASM Research Chemicals GmbH and Co. 
Perspective Biosystem PNA kit (Fmoc/Bhoc monomers, HATU activator, Base 
solution (0.2 M DIEA, 0.3 M lutidine), Wash B (anhydrous DMF), DIEA, Capping 
Solution (5% Ac2O, 6% lutidine), Deblock solution (20% piperidine in DMF)) was 
purchased from PRIMM (Milan, Italy). Boc-L-DAB(Fmoc)-OH and Boc-D-DAB(Fmoc)-
OH was from Bachem. Dry CH3CN, DCM (for synthesis), DIEA and TFA (for HPLC) 
were from Romil. Deuterated solvents (DMSO, methanol) and TMP were from 
Aldrich. Thin-layer chromatography (TLC) analyses were performed on silica gel 
Macherey–Nagel G-25 UV254 plates (0.25-mm  thick) visualized by UV light and by a 
ninhydrin staining solution. The reactions were monitored by TLC until all starting 
material had been consumed. Solvents for TLC analyses, and diethyl ether were 
from Carlo Erba. dA12 and A12  were purchased from Biomers (Ulm, Germany).  
 
5.2  Instrumentations 
1HNMR and  13C NMR spectra were recorded at  25 °C on Varian unity 300 MHz and 
Varian Inova 600 MHz spectrometers. Chemical shifts (δ) are given in parts per 
million (ppm) and all coupling constants (J) in Hz. Proton chemical shifts were 
referenced to residual CHD2SOCD3 (δ = 2.49, quin) and CHD2OD (δ = 3.30, quin) 
signals.13C NMR chemical shifts were referenced to the solvent (CD3SOCD3: δ = 
39.5, sept; CD3OD: δ = 49.0, sept). aegPNA oligomers were assembled on solid 
phase with an Applied  Biosystems Expedite 8909 oligosynthesizer. Crude samples 
containing  PNA oligomers were centrifuged  for 4 min at 4000 rpm (Z 200 A, 
Hermle). Products were analyzed and characterized  by LC-MS, performed on an 
MSQ mass spectrometer (Thermo Electron, Milan, Italy) equipped with an ESI source 
operating at 3 kV needle voltage and 320 °C, and with a complete Surveyor HPLC 
system, comprising an MS pump, an autosampler and a photo diode array (PDA) 
detector, by using a Phenomenex Jupiter C18 300 A° (5 μm, 4.6 × 150 mm) column. 
Gradient elution was performed at 40 °C (monitoring at 260 nm) by building up a 
gradient starting with buffer A (0.05% TFA in water) and applying buffer B (0.05% 
TFA in acetonitrile) with a flow rate of 0.8 ml/min.  
Semipreparative purifications were performed by RP-HPLC on a Shimadzu LC-8A 
equipped  with an SPD-10A VP UV–vis detector, and on a Hewlett Packard/Agilent 
1100 series equipped with a diode array detector, by using a Phenomenex Jupiter 
C18 300 A° (10 μm, 10 × 250 mm) column. Gradient elution was performed at 45 °C 
(monitoring at 260 nm) by building up a gradient starting with buffer A (0.1% TFA in 
water) and applying buffer B (0.1% TFA in acetonitrile) with a flow rate of 4 ml/min. 
Samples containing PNAs (crude or purified) were lyophilized in an FD4 freeze dryer 
(Heto Lab Equipment) for 16 h. CD spectra were obtained on a Jasco J-810 
spectropolarimeter. UV spectra and UV-melting experiments were recorded on a 
UV–Vis Jasco model V-550 spectrophotometer equipped with a Peltier ETC- 505T 
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temperature controller. UV and CD measurements were performed in Hellma quartz 
Suprasil cells, with a light path of  1 cm  and  2 × 0.4375 cm (Tandem cell). Dynamic 
light-scattering (DLS) experiments were performed on a Viscotek 802 DLS instrument 
equipped with a 50 mW internal laser operating at a wavelength of 630 nm. 
 
5.3 Methods 
 
Synthesis of the dabPNA monomers 
Commercial Boc-L-DAB(Fmoc)-OH(200 mg, 0.45 mmol) and Boc-D-DAB(Fmoc)-OH 
(200 mg, 0.45 mmol) were separately reacted with a solution of TFA/DCM/H2O 4.5 : 
4.5 : 1 at 50 ◦C for  1h, and subsequently treated as we recently reported (Roviello et 
al., 2006). The D- and L-products obtained, dissolved in dry DMF (8 ml) and DIEA 
(0.6 eq, 41.2 μl, 0.24 mmol) and TMP (0.6 eq, 33.3 μl, 0.24 mmol), were separately 
reacted with both the thymin-1-acetic acid (2 eq, 149 mg, 0.81 mmol) and the Bhoc-
protected adenin-9-acetic acid (2 eq, 149 mg, 0.81 mmol), previously preactivated 
with HATU (1.9 eq, 293 mg, 0.77 mmol), DIEA (2 eq, 137.5 μl, 0.81 mmol), and TMP 
(2 eq, 107.0 μl, 0.81 mmol) for 2 min. After  2 h the reaction was quenched by 
removing the solvent under vacuum, suspending in H2O/CH3CN (7 : 3) and 
lyophilizing. The lyophilized crude was resuspended in cold water, sonicated, 
transferred into a falcon tube, and then centrifuged at 1200 rpm at room temperature. 
After the supernatant was removed, the white pellet obtained  was washed twice with 
cold water and dried. In this way, products 4 and 9 were obtained as almost pure 
samples (95% purity), while for 12 and 12‟ the white pellets were dissolved in 
H2O/CH3CN 7 : 3 (v/v) and purified by semi-preparative RP-HPLC using increasing 
amounts of acetonitrile (from 35 to 75%in 25 min) in water at 25 ◦C with a flow rate of 
4 mlmin−1. Pure samples 3 and 4 were obtained  as white powders in 51 and 49% 
yields, respectively. Compound  4: the  LC-ESI-MS    m/z: 507.32 (found), 507.52 
(expected for MH+); δH (600 MHz, DMSO-d6) 11.35 (1H, br s, NH thymine), 8.54 
(1H, br s, NH amide), 7.98 (2H, d, J = 7.3, aromatic CH Fmoc), 7.77 (2H, d, J = 7.3, 
aromatic CH Fmoc), 7.51 (2H, t, J = 7.3, aromatic CH Fmoc), 7.49–7.51 (1H, m, 
Fmoc-NH), 7.42 (2H, t, J = 7.3, aromatic CH Fmoc), 7.41 (1H, s, CH thymine), 4.43 
(2H, s, CH2 acetyl linker), 4.05–4.50 (4H, m, FmocCH-CH2 and CHα), 3.14 (2H, m, 
CH2NH), 2.00 (1H, m, part of an AB system  centred at 1.91, CH2CHα), 1.83 (1H, m, 
part of an AB system centred at 1.91, CH2CHα), 1.82 (3H, s, CH3 thymine); δH (600 
MHz, CD3OD) 7.78 (2H, d, J = 7.3, aromatic CH Fmoc), 7.64 (2H, d, J = 7.3, aromatic 
CH Fmoc), 7.38 (2H, t, J = 7.3, aromatic CH Fmoc), 7.36 (1H, s, CH thymine), 7.30 
(2H, t, J = 7.3, aromatic CH Fmoc), 4.47 (2H, s, CH2 acetyl linker), 4.19–4.50 (4H, m, 
FmocCH-CH2 and CHα), 3.19 (1H, m, part of an AB system centred at 3.22, CH2NH), 
3.25 (1H, m, part of an AB system centred at 3.22, CH2NH), 2.11 (1H, m, part of an 
AB system centred at 1.98, CH2CHα), 1.85 (1H, m, part of an AB system centred at 
1.98, CH2CHα), 1.84 (3H, s, CH3 thymine); δC (150 MHz, DMSO-d6) 170.98 (COOH), 
168.48 (CH2CONH), 160.10 (thymine C-4), 155.00 (OCONH), 147.96 (aromatic 
Fmoc 2C), 147.89 (thymine C-2), 146.36 (aromatic Fmoc 2C), 144.73 (thymine C-6), 
131.65 (aromatic Fmoc 2CH), 131.11 (aromatic Fmoc 2CH), 129.18 (aromatic Fmoc 
2CH), 124.15 (aromatic Fmoc 2CH), 111.96 (thymine C-5), 69.40 (Fmoc CH2), 53.02 
(CH2 acetyl linker), 50.73 (CHα), 44.1 (Fmoc CH), 41.30 (CH2NH), 22.56 (CH2CHα), 
15.91 (thymine CH3). Compound  9: the LC-ESI-MS were almost identical to the 
enantiomer 4; compound 12: LC-ESI-MS m/z: 726.36 (found), 726.00 (expected for 
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MH+); δH (600 MHz, DMSO-d6) 8.43 (1H, s, H-8 adenine), 8.22 (1H, s, H-2 
adenine), 7.13–7.75 (18H, aromatic CH Fmoc and Bhoc, and 1H Fmoc-NH), 4.47 
(2H, s, CH2 acetyl linker), 4.19–4.50 (4H, m, FmocCH-CH2 and CHα), 3.19 (1H, m, 
part of an AB system centered at 3.22, CH2NH), 3.25 (1H,m, part of an AB system 
centered at 3.22, CH2NH), 2.11 (1H, m, CH2CHα), 1.85 (1H, m, CH2CHα); Compound  
12‟: the LC-ESI-MS were almost identical to the enantiomer 12. 
Solid-phase Synthesis of Oligomers 5–8 (Table 1) 
Solid support functionalization and manual solid-phase oligomerizations were carried 
out in short PP columns (4 ml) equipped with a PTFE filter, a stopcock and a cap. 
Solid support functionalization: Rink-amide resin (0.50 mmol NH2/g, 128 mg) was 
functionalized with a lysine (Fmoc- Lys(Boc)-OH, 0.5 equiv., 14.8 mg, 32 μmol) using 
PyBOP (0.5 equiv., 16.8 mg, 32 μmol) as activating agent and DIEA (1 equiv., 12 μl, 
64 μmol) as base for 30 min at room temperature. Capping of the unreacted amino 
groups was performed with Ac2O (20%)/DIEA (5%) in DMF. Loading of the resin was 
checked by measuring the absorbance of the released Fmoc group (ε301 = 7800, 
quantitative yield) after treatment with a solution of piperidine (30%) in DMF (UV 
Fmoc test) and the resultant reduced to 0.25 mmol/g with respect to the initial 
functionalization. Automatic solid-phase assembly of the aegPNAs was performed on 
an Expedite 8909 nucleic acid synthesis system using a standard 2-μmol-scale 
protocol and Fmoc chemistry leaving the final Fmoc on, in order to evaluate SPS 
yields by the UV Fmoc test. Manual couplings of dabPNA monomers were monitored 
by the UV Fmoc test in order to evaluate the incorporation yields of the new 
monomer. A glycine residue (3 equiv.) was attached to the N-terminus of all the 
oligomers by using PyBOP (3 equiv.)/DIEA (6 equiv.) in DMF as the activating 
system. After removal and quantification of the Fmoc group, all oligomers were 
cleaved from the resin and deprotected under acidic conditions (TFA/m-cresol 4 : 1 
v/v). The oligomers were isolated by precipitation with cold diethyl ether, 
centrifugation and lyophilization. Purified oligomers (semipreparative HPLC) were 
quantified and characterized by LC-ESI-MS. 
H-Gly-(tL-dab)12-Lys-NH2 5. (tL-dab)12 was assembled manually on Rink-amide-Lys-
NH2 resin (0.25 mmol/g, 32 mg) using the following protocol: 0.2 M Fmoc-tdab-OH 
monomer in NMP (3 equiv., 120 μl, 24 μmol), 0.2 M PyBOP in DMF (3 equiv., 120 μl, 
24 μmol) and 0.2 M NMM in DMF (6 equiv., 240 μl, 48 μmol) were added in 
sequence to the resin and the coupling was left for 30 min with shaking at room 
temperature. Successively, the unreacted amino groups were capped with PNA Cap 
solution for 5 min. Fmoc removal was accomplished with PNA Deblock solution (5 
min) and was monitored at every step by UV measurements: average yield for the 
first six steps was 96%, while for the last six steps a lowering of the yields from 96 to 
70% was observed probably because of the enhanced aggregation tendency of the 
increasing homothymine chain (overall yield: 25%). Yield of the last coupling with 
glycine was 97%. After cleavage and deprotection, the oligomer 5 was purified by 
semipreparative RP-HPLC using a linear gradient of 8% (for 5 min) to 25% B in A 
over 30 min: tR = 31.0 min; UV quantification of the purified product gave 100 nmol of 
6; ESI-MS (Figure 3) m/z: 1134.8 (found), 1133.4 (expected for [M + 3H]3+).       
 H-Gly-t12-Lys-NH2 6. Standard t12 aegPNA was assembled on Rink-amide-Lys-NH2 
resin (0.25 mmol/g, 32 mg) on an automatic synthesizer. After the synthesis was 
complete, the final Fmoc was left on and removed manually to perform the Fmoc UV 
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test. The overall yield of t12 was only 18% probably because the flow through 
synthesis of the automatic synthesizer enhances the aggregation problems of the 
homothymine sequence. Glycine was incorporated manually as the last residue with 
high efficiency (98% yield). The cleaved and deprotected oligomer was purified by 
semipreparative RP-HPLC using a linear gradient of 8% (for 5 min) to 20% B in A 
over 30 min: tR = 27.9 min; UV quantification of the purified product gave 60 nmol of 
8; ESIMS m/z: 1132.0 (found), 1697.1 (found), 1133.4 (expected for [M + 3H]3+), 
1699.7 (expected for [M+ 2H]2+). 
 
H-Gly-(tdab)t11-Lys-NH2 7. The aegPNA part of 7 was assembled on Rink-amide-
Lys-NH2 resin (0.25 mmol/g, 32 mg) in an automatic synthesizer leaving the final 
Fmoc on (yield: 20%), while the dabPNA monomer was attached manually as the last 
residue following the protocol described for 5 (yield: 95%). After the last coupling with 
glycine, an overall yield of 18% was obtained. After cleavage and deprotection, the 
oligomer was purified by semipreparative RP-HPLC using a linear gradient of 8% (for 
5 min) to 17% B in A over 35 min: tR = 29.8 min; UV quantification of the purified 
product gave 70 nmol of 7; ESI-MS m/z: 1133.0 (found), 1699.8 (found), 1133.4 
(expectedfor [M+ 3H]3+), 1699.7 (expected for [M+ 2H]2+). 
 
H-G-t6tL-dabt5-K-NH2 8. The synthesis of the aegPNA part of 8 was performed on 
Rink-amide-Lys-NH2 resin (0.25 mmol/g, 32 mg) by the automatic synthesizer except 
for the dabPNA monomer, which was attached manually in the middle of the aegPNA 
sequence (overall yield: 20%). Glycine was incorporated manually as the last residue 
with 95% yield. The cleaved and deprotected oligomer was purified by 
semipreparative RP-HPLC using a linear gradient of 7% (for 5 min) to 19% B in A 
over 40 min: tR = 30.1 min; UV quantification of the purified product gave 80 nmol of 
8; ESIMS m/z: 1132.8 (found), 1698.5 (found), 1133.4 (expected for [M + 3H]3+), 
1699.7 (expected for [M+ 2H]2+). 
 
Solid Phase Syntheses of dabPNA oligomers (10-15) 
Solid phase oligomerizations were carried out in short PP columns (4 ml) equipped 
with a polytetrafluoroethylene (PTFE) filter, a stopcock and a cap. Solid support 
functionalization: Rink-amide resin (0.50 mmol NH2/g, 128 mg) was functionalized 
with a lysine (Fmoc-Lys(Boc)-OH, 0.5 eq, 14.8 mg, 32 μmol) using PyBOP (0.5 eq, 
16.8 mg, 32 μmol) as activating agent and DIEA (1 eq, 12 μl, 64 μmol) as base for 30 
min at room temperature. Capping of the unreacted amino groups was performed 
with Ac2O (20%)/DIEA (5%) in DMF. Loading of the resin was checked by measuring 
the absorbance of the released Fmoc group (ε301 = 7800, quantitative yield) after 
treatment with a solution of piperidine (30%) in DMF (UV Fmoc test)andresulted 
reduced to 0.25 mmolg−1 with respect to the initial functionalization. DabPNA 
monomers were coupled manually to the solid support using the following protocol: a 
mixture of the monomer (75 μl of a 0.2 M solution in DMF, 15 μmol, 3 eq), HATU (75 
μl of a 0.2 M solution in DMF, 15 μmol, 3 eq), and DMF (100 μl) was introduced into 
the reactor containing the Rink-amide-Lys-NH2 resin (0.25 mmol g−1, 20mg,5 μmol). 
Successively, 75 μl (15 μmol, 3 eq) of the TMP solution (0.2 M in NMP) was added to 
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the stirred reaction in four portions over 1 h. After the coupling step, unreacted amino 
groups were capped with PNA capping solution for 5 min. Fmoc removal was 
accomplished with PNA deblocking solution for 10 min, and was monitored by UV 
Fmoc test to evaluate the incorporation yields of the monomers. A glycine residue (3 
eq) was attached to the N-terminus of all the oligomers by using PyBOP (3 eq)/DIEA 
(6 eq) as activating system in DMF. After removal and quantification of the final Fmoc 
group, all oligomers were cleaved from the resin and deprotected under acidic 
conditions (TFA/m-cresol 4 : 1 v/v). After precipitation with cold diethyl ether, 
centrifugation and lyophilization, crude oligomers, were purified by semi-preparative 
RP-HPLC at 45 °C using a linear gradient of 5% (for 5 min) to 22% acetonitrile (0.1% 
TFA) in water (0.1% TFA) over 25 min. Purified oligomers were quantified by UV and 
characterized by LC-ESI-MS. UV quantification was performed by dissolving 
oligomers in a known amount of milliQ water and measuring the A260 at 85 °C, using 
as extinction coefficients those of the aegPNA monomers (ε260 = 8600 cm
−1 M−1 for 
thymine monomer, ε260 = 13 700 cm
−1 M−1 for adenine monomer). H-G-(tL−dab)6-K-NH2 
: HPLC tR = 25 min; UV quantification (ε260 = 51 600 cm
−1 M−1) of the purified product 
gave 110 nmol (2.2%yield); ESI-MS m/z: 900.07 (found), 900.8 (expected for [M + 
2H]2+). H-G-(tD−dab)6-K-NH2 : HPLC tR = 25 min; UV quantification of the purified 
product gave 120 nmol (2.4% yield); ESI-MS m/z: 900.17 (found), 900.8 (expected 
for [M + 2H]2+). H-G-(aL−dab)6-K-NH2 : HPLC tR = 20 min; UV quantification (ε260 = 82 
200 cm−1 M−1) of the purified product gave 204 nmol (4.1%yield); ESI-MS m/z: 927.9 
(found), 927.08 (expected for [M + 2H]2+). H-G-(tL−dab-tD−dab)3-K-NH2 : HPLC tR = 23 
min; UV quantification of the purified product gave 95 nmol (1.9% yield); ESI-MS m/z: 
900.30 (found), 900.8 (expected for [M + 2H]2+). H-G-(aL−dab-aD−dab)3-K-NH2 : HPLC tR 
= 22 min; UV quantification of the purified product gave 130 nmol (2.6% yield); ESI-
MS m/z: 928.0 (found), 927.08 (expected for [M + 2H]2+). H-G-(aL−dab-tD−dab)3-K-NH2 : 
HPLC tR = 22 min; UV quantification (ε260 = 66 900 cm
−1 M−1) of the purified product 
gave 140  nmol (2.8% yield); ESI-MS m/z: 915.3 (found), 914.8 (expected for [M + 
2H]2+). 
 
UV and CD Studies  
Annealing of all PNA oligomers  with complementary dA12 was performed by mixing 
equimolar amounts of the two strands in 10 mM phosphate buffer at pH 7.5 to 
achieve a duplex concentration of 4 μM. The solution was heated at 85 °C (5 min) 
and then allowed to cool slowly to room temperature. Thermal melting curves  were 
obtained by recording the UV absorbance at  260 nm while the temperature was 
ramped from 20 to 97 °C at a rate of 0.5°C/min. Tm values, calculated by the first 
derivative method. CD spectrum   was recorded from 320 to 200 nm at 20 °C under 
the following conditions: scan speed 50 nm/min; data pitch 2 nm; bandwidth 2 nm; 
response 4 s; accumulations 3.  
Annealing of complementary dabPNA oligomers was performed by mixing equimolar 
amounts of the two strands in 10 mM phosphate buffer (pH 7.5). The solution was 
heated at 85 ◦C (5 min), allowed to cool slowly to room temperature and then kept at 
4 ◦C for 2 h. Thermal-melting curves were obtained by recording the UV absorbance 
at  260 nm, while the temperature was increased at a rate of 0.5 ◦Cmin−1. Tm values 
were calculated by the first derivative plot. CD spectra were recorded from 360 to 
200 nm: scan speed 50 nm min−1, data pitch 2 nm, band width 2 nm, response 4 s, 
ten accumulations. CD-binding experiments were performed with a tandem cell which 
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allows to record the „sum‟ spectrum of  two separated sample solutions kept each in 
one of the two reservoirs of the cell, and the „mix‟ spectrum obtained after the cell 
was turned upside down to allow the mixing of the two samples. 
 
Dynamic Light-Scattering Experiments 
 
Hydrodynamic radii of the nucleopeptide complexes were measured via scattered 
light recorded at 90◦ angle to incident radiation at a wavelength of 630 nm. From 
standard autocorrelation functions, measured diffusion coefficients were related to 
particle hydrodynamic radius via the Stokes–Einstein equation. 
 
Serum Stability Assay 
Nucleopeptide (aL−dab-tD−dab)3 (10 μl, 200 μM) was added to 90 μl of 100% fresh 
human serum ((aL−dab-tD−dab)3 was 10 μM in 90% serum) in a microvial and the 
mixture was incubated at 37 ◦C. Aliquots of 10 μl each were taken at times = 0, 1, 2, 
24, and 48 h, quenched with 10 μl of 7 M urea solution, kept at 95 ◦C for 3 min, and 
then stored at −20 ◦C until subsequent analysis. The withdrawn samples were 
analyzed by RP-HPLC on a Phenomenex Juppiter C18 300 Å (5 μm, 4.6 × 250 mm) 
column using a linear gradient of 8% (for 5 min) to 20% acetonitrile (0.1% TFA) in 
water (0.1% TFA) over 30 min. 
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Abbreviations 
 
A   Adenine 
ACN   Acetonitrile 
Aeg   N-(2-aminoethyl) glycine 
Bhoc   Benzhydryloxycarbonyl 
Boc   tert-Butyloxycarbonyl 
C   Cytosine 
Cbz   Benzyloxycarbonyl 
CD   Circular Dichroism 
DABA   Acido 2,4-diamminobutanoico 
dabPNA                  diaminobutyrylPNA 
DCM   Dichloromethane 
DIPEA/DIEA  Diisopropylethylamine 
DMF   N,N-dimethylformamide 
DMSO  Dimethylsulphoxide 
ESI   Electrospray Ionization  
FDA   Food and Drug Administration 
FISH   Fluorescent In Situ Hybridization 
Fmoc   9-Fluorenylmethoxycarbonyl 
G   Guanine 
HATU O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
LC Liquid Chromatography  
LNA   Locked Nucleic Acid 
MP   Morpholino phosphoramidite 
MS   Mass Spectrometry 
NMP   1-Methyl-2-pyrrolidinone 
NMR   Nuclear Magnetic Resonance 
ODN   Oligodeoxyribonucleotide 
PCR   Polymerase Chain Reaction 
PDBA   Acido poli(2,4-diaminobutanoico) 
PNA   Peptide (polyamide) Nucleic Acid 
PP   Polipropilene 
PTFE   Politetrafluorethylene 
PyBop Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate 
RP-HPLC  Reverse Phase-High Performance Liquid Chromatography 
SNP   Single Nucleotide Polymorphism  
T   Thymine 
TEM   Transmission Electron Microscope 
TFA   Trifluoroacetic acid 
TLC   Thin Layer Chromatography 
TMP   2,4,6, trimetilpiridine 
UV   Ultraviolet 
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